

1 **Title:** Paving the way for human vaccination against Rift Valley fever virus:

2 A systematic literature review of RVFV epidemiology from 1999 to 2021

3

4 **Short Title:** Review of RVFV epidemiology for a human vaccination trial

5 **Authors:** Keli N. Gerken<sup>1</sup>, A. Desirée LaBeaud<sup>1</sup>, Henshaw Mandi<sup>2</sup>, Maïna L’Azou

6 Jackson<sup>3</sup>, J. Gabrielle Breugelmans<sup>2</sup>, Charles H. King<sup>4\*</sup>

7 <sup>1</sup>Division of Pediatric Infectious Diseases, Department of Pediatrics, Stanford University

8 School of Medicine, Stanford, California, USA

9 <sup>2</sup>Coalition for Epidemic Preparedness Innovations (CEPI), Oslo, Norway

10 <sup>3</sup>Coalition for Epidemic Preparedness Innovations (CEPI), London, UK

11 <sup>4</sup>Center for Global Health and Diseases, Department of Pathology, Case Western

12 Reserve University School of Medicine, Cleveland, Ohio, USA

13

14 Word count, abstract: 335

15 Word count, manuscript: 12246

16 Tables: 3 (13 supplementary)

17 Figures: 10 (3 supplementary)

18

19 \*Corresponding author:

20 Email: [charlesking48@gmail.com](mailto:charlesking48@gmail.com) (CHK)

21

22

## 23 **Abstract**

24 **Background:** Rift Valley fever virus (RVFV) is a lethal threat to humans and  
25 livestock in many parts of Africa, the Arabian Peninsula, and the Indian Ocean. This  
26 systematic review's objective was to consolidate understanding of RVFV epidemiology  
27 during 1999-2021 and highlight knowledge gaps relevant to plans for human vaccine  
28 trials.

29 **Methodology/Principal Findings:** The review is registered with PROSPERO  
30 (CRD42020221622). Reports of RVFV infection or exposure among humans, animals,  
31 and/or vectors in Africa, the Arabian Peninsula, and the Indian Ocean during the period  
32 January 1999 to June 2021 were eligible for inclusion. Online databases were searched  
33 for publications, and supplemental materials were recovered from official reports and  
34 research colleagues. Exposures were classified into five groups: 1) acute human RVF  
35 cases, 2) acute animal cases, 3) human RVFV sero-surveys, 4) animal sero-surveys,  
36 and 5) arthropod infections. Human risk factors, circulating RVFV lineages, and  
37 surveillance methods were also tabulated. In meta-analysis of risks, summary odds  
38 ratios were computed using random-effects modeling. 1104 unique human or animal  
39 RVFV transmission events were reported in 39 countries during 1999-2021. Outbreaks  
40 among humans or animals occurred at rates of 5.8/year and 12.4/year, respectively,  
41 with Mauritania, Madagascar, Kenya, South Africa, and Sudan having the most human  
42 outbreak years. Men had greater odds of RVFV infection than women, and animal  
43 contact, butchering, milking, and handling aborted material were significantly associated  
44 with greater odds of exposure. Animal infection risk was linked to location, proximity to

45 water, and exposure to other herds or wildlife. RVFV was detected in a variety of  
46 mosquito vectors during interepidemic periods, confirming ongoing transmission.

47 **Conclusions/Significance:** With broad variability in surveillance, case finding,  
48 survey design, and RVFV case confirmation, combined with uncertainty about  
49 populations-at-risk, there were inconsistent results from location to location. However, it  
50 was evident that RVFV transmission is expanding its range and frequency. Gaps  
51 assessment indicated the need to harmonize human and animal surveillance and  
52 improve diagnostics and genotyping. Given the frequency of RVFV outbreaks, human  
53 vaccination has strong potential to mitigate the impact of this now widely endemic  
54 disease.

55

## 56 **Author Summary**

57 Rift Valley fever virus (RVFV) is a globally important mosquito-transmitted  
58 zoonosis that is also directly transmissible via aerosolization of body fluids from infected  
59 animals. RVFV outbreaks cause mass mortality of young livestock and pregnancy  
60 losses in both humans and animals. Severe human cases also result in hemorrhagic  
61 fever, encephalitis, and death. Loss of livestock additionally threatens the livelihood of  
62 people who depend on animals for income and food. In endemic areas, initiation of  
63 RVFV outbreaks is connected to weather events that cause excess rainfall, leading to  
64 flooding and subsequent mosquito blooms. However, the natural cycle of RVFV  
65 transmission is complex, requiring congregation of susceptible mammalian hosts and  
66 mosquito vectors in suitable environments. Several human vaccine candidates are in  
67 different stages of development, but none are yet licensed for use in human

68 populations. In this systematic review, we assessed the 1999-2021 frequency and  
69 distribution of RVFV outbreaks among humans, animals, and vectors to identify  
70 potential locations and population targets for a human RVFV vaccine efficacy trial. It  
71 focuses on current understanding of RVFV epidemiology and the identification of gaps  
72 that pose critical barriers to controlling expansion of RVFV and implementing new  
73 protective measures including human vaccination.

74

75

## 76 **Introduction**

77 Rift Valley fever virus (RVFV) remains an important emerging arboviral pathogen  
78 due to its recent geographic spread and its combined disease and financial impacts on  
79 vulnerable human populations [1]. Specifically, RVFV is listed as a priority pathogen by  
80 the World Health Organization (WHO), the Food and Agriculture Organization of the  
81 United Nations (FAO), and the U.S. Centers for Disease Control and Prevention (CDC)  
82 because of its ability to cause life-threatening hemorrhagic fever and encephalitis in  
83 humans [2, 3], its epidemic potential to cause severe harm to livestock [4, 5], and its  
84 potential for non-vector aerosol spread during epizootics and epidemics [6, 7]. The RVF  
85 virus is a member of the *Phlebovirus* genus, with three main lineages, with East African,  
86 West African, and Southern African groupings. In the absence of efficacious human  
87 drugs and/or vaccines against RVF, the virus has the potential to trigger significant  
88 public health emergencies in affected areas.

89 RVFV was first identified in 1931 during an investigation into an epidemic of  
90 fatalities among sheep on a farm in the Rift Valley Province of Kenya [8]. Since that

91 time, its spatial range has continued to expand from East Africa into southern Africa,  
92 West Africa, and North Africa, and more recently outside Africa to the Arabian Peninsula  
93 [6, 7, 9]. RVFV can infect a wide range of mammalian hosts [10] and can be carried by  
94 many arthropod vectors. Floodwater *Aedes spp.* are important in maintenance during  
95 interepidemic periods, whereas other Diptera serve as secondary vectors during  
96 outbreaks in sub-tropical and temperate regions of the world [11-15]. RVFV results in  
97 lower case fatality rates (CFR) compared to other hemorrhagic fever viruses [4], but its  
98 outbreaks have profound compounding effects on human subsistence (from loss of  
99 livestock) and on national economies, related to livestock export bans [16-19].

100 The critical environmental reservoir of RVFV is presently unknown. Humans  
101 become infected either through the bite of an infected vector or through exposure to  
102 infectious animal tissues or bodily fluids such as abortus, birthing fluids, meat, milk, or  
103 blood aerosolized during slaughtering. Other than *in utero* transmission, there is no  
104 evidence for human-human transmission of RVFV [4]. Those infected either remain  
105 minimally symptomatic or develop a mild form of the disease Rift Valley fever (RVF)  
106 (96% of patients), which is characterized by a febrile syndrome with sudden onset of flu-  
107 like fever, muscle pain, joint pain, and headache [4]. Some patients develop neck  
108 stiffness, sensitivity to light, loss of appetite and vomiting and therefore RVF can be  
109 mistaken for meningitis [20]. While most human cases are relatively mild, a small  
110 percentage of patients will develop a much more severe form of the disease [21]. This  
111 usually appears as one (or more) of three distinct syndromes: ocular (eye) disease  
112 (0.5–2% of patients), meningoencephalitis (fewer than 1% of patients) or hemorrhagic  
113 fever (fewer than 1% of patients) [4].

114 Equally important is the lethal threat to peoples' livestock. RVFV spread into  
115 naïve ecosystems is driven by infected animal movement, and potentially via infected  
116 vectors [22], and can result in death of between 70-90% of young ruminants, with sheep  
117 the most affected, and loss of pregnancy in nearly 100% of pregnant animals [23].

118 Outbreaks in humans and in animals do not occur at random. Instead they are  
119 strongly linked to excess rainfall and to local flooding events [24] and the consequent  
120 rise in mosquito abundance [25-32]. In addition, there is mounting evidence that  
121 suggests that there is continuing low-level RVFV transmission to humans and to  
122 animals between recognized epidemic periods [33-49]. Undetected infections,  
123 particularly in livestock, provide an important reservoir for recurrent outbreaks, leading  
124 to a continuing threat of disease in economically marginal communities and risk of  
125 further geographical expansion.

126 With no human-use vaccines available, the Coalition for Epidemic Preparedness  
127 Innovations (CEPI) expanded its list of target diseases to include RVF in January 2019.  
128 To date, CEPI has supported two programs to advance human RVF vaccines in  
129 collaboration with Wageningen Bioveterinary Research (WBVR), a division of  
130 Wageningen University, and Colorado State University (CSU). Both vaccine candidates  
131 are currently in the preclinical stages of development. Elsewhere, the University of  
132 Oxford has developed a single dose ChAdOx1 RVF vectored vaccine that is currently in  
133 phase 1 studies to determine the safety and immunogenicity among healthy adult  
134 volunteers (<https://clinicaltrials.gov/ct2/show/NCT04672824>). Previously, the US Army  
135 Medical Research Institute of Infectious Diseases (USAMRIID) developed an improved  
136 version of inactivated RVF vaccine, TSI-GSD-200, which, from early 1986 to late 1997

137 was given to 598 at-risk workers in their facilities, which provided effective antibody  
138 immunity after a three dose regimen [50]. However, to date, none of these vaccines has  
139 been trialed in endemic human populations, and none has undergone phase III clinical  
140 trials in order to be licensed for general use. A major challenge in planning clinical trials  
141 is the lack of precise understanding of the RVFV epidemiology and the unpredictability  
142 of outbreaks. Thus, there was need for an in depth review of existing epidemiological  
143 data and identification of remaining key knowledge gaps to further vaccine  
144 development.

145 The specific objective of this study was to consolidate the understanding of  
146 recent RVF epidemiology over the recent 1999-2021 period. We sought to catalogue  
147 the variability of national/regional incidence and prevalence, human risk factors and  
148 populations at risk, the geospatial distribution of RVF serotypes/lineages, and the  
149 present day national and regional human and animal RVF/viral hemorrhagic fever  
150 surveillance systems. The systematic review also highlighted current knowledge gaps in  
151 RVFV epidemiology to establish the major challenges remaining for current efforts in  
152 development and testing of human vaccines.

153

## 154 **Methods**

155 To meet our study goals, we performed a systematic review of the available  
156 published literature as well as governmental monitoring and media reports of RVF  
157 activity during the period 1999-2021. The study results are reported according to the  
158 2020 Preferred Reporting Items for Systematic Reviews and Meta-Analyses (PRISMA  
159 2020) guidelines [51]. See S1 Table for details.

160           **Inclusion/exclusion criteria.** Studies included in the review were those that  
161 contained reports of human, animal, and/or vector RVFV infection or exposure among  
162 individuals (of any age) in countries across Africa, the Arabian Peninsula, and the Indian  
163 Ocean where RVFV transmission was detected during the period January 1<sup>st</sup> 1999 to  
164 June 1<sup>st</sup> 2021, including historical, observational, and prospective studies. Serosurveys  
165 from outside this target area (Spain [52, 53], Poland [54], Korea [55], and Jordan [56])  
166 were also catalogued, although not formally included in our analysis. Reports containing  
167 primary human seroprevalence or incidence data, reported RVF outbreaks or cases,  
168 details of RVF transmission, RVFV lineage distribution, and/or risk factors were  
169 included. Reports of infections among regional livestock and wildlife during the same  
170 period were also included.

171           The primary objective was to obtain population-based survey data. However,  
172 georeferenced location-specific case reports were also included in spatiotemporal  
173 analysis. There was no restriction according to the language of publication.

174           Excluded studies were those that reported laboratory-based studies or  
175 intervention trials among experimental animals in controlled settings. Reports, reviews,  
176 or opinion articles without primary data were also excluded.

177           **Information sources and search strategy.** To maximize detection of eligible RVFV  
178 transmission studies, we searched the online databases PubMed, Web of Science,  
179 African Journals Online, The Cumulative Index to Nursing and Allied Health Literature  
180 (CINAHL), The Scientific Electronic Library Online (SciELO), Elsevier, ResearchGate,  
181 and the Program for Monitoring Emerging Diseases (ProMED) listserv site. Animal  
182 outbreak data recorded by the World Organization for Animal Health (OIE) was



183 recovered from their databases, the 2005-2021 WAHIS (<https://wahis.oie.int/#/home>),  
184 and the older Handistatus II database (<https://web.oie.int/hs2>). Other sources of papers  
185 and reports that were also retrieved included: i) polling colleagues involved in RVF  
186 research or control for any non-indexed 'grey literature', ii) using Google Scholar  
187 referrals for 'similar papers', iii) scanning of literature found in personal archives, and iv)  
188 obtaining non-indexed citations found among the reference lists of the papers reviewed  
189 in our study. Details of the information sources and search strategy used are available  
190 in S1 Text.

191 **Selection process.** Review of titles and abstracts was performed by two trained  
192 reviewers who independently searched for data content meeting study requirements.  
193 The studies found potentially suitable for inclusion after title-abstract review were then  
194 obtained for full-text review from online or library sources. Where a single report  
195 contained data on multiple individual community surveys, each of these surveys was  
196 separately abstracted and given a unique ID number for inclusion in sub-group  
197 comparison analyses. Studies with insufficient details of the incidence or prevalence of  
198 RVFV infection were not included, and cases of duplicate publication or extended  
199 analysis of previously published data were removed from the list of selected references  
200 for this review. Full listings of included and excluded references are provided as  
201 Supporting Information files S2 and S3 Tables.

202 **Data collection process.** Included papers were abstracted by two independent  
203 reviewers, and their relevant features entered into a purpose-built database created with  
204 Google Forms. The entries were then stored in a shared master spreadsheet in Google  
205 Sheets. The included papers and data registry downloads were archived in electronic

206 text (pdf) or spreadsheet formats at the Department of Pediatrics, Stanford University  
207 School of Medicine, and at the Center for Global Health and Diseases, Case Western  
208 Reserve University.

209 **Data items.** For the human and animal RVFV exposures or clinical cases reported,  
210 information was entered into the database based on UN geographic region  
211 (<https://unstats.un.org/unsd/methodology/m49>), country, and the sub-national  
212 administrative location details that were reported. Islands in the Indian Ocean, normally  
213 classified as ‘Eastern Africa’ by the UN, were grouped separately for our analyses. The  
214 beginning and ending month and year of the reported RVF activity or exposure study  
215 were recorded, as well as information about whether the event was a recurrence of  
216 transmission in a previously affected area, whether there had been flooding before the  
217 event, and whether the period involved an El Nino-Southern Oscillation (ENSO) event.  
218 When outbreaks spanned more than one calendar year, the year of onset was used to  
219 classify the event. Study design and the eligible study population were recorded for  
220 each report and whether the report involved human cases, domestic or wildlife animals,  
221 or arthropod vectors, and the number of affected individuals by species. Where  
222 available, age and gender distributions were captured for both animal and human  
223 studies, along with any potential risk factors that were studied, and which were found to  
224 be significant by that study. Factors evaluated for human exposure risk were age and  
225 age class, gender, occupation, socio-economic status, and participation in the animal  
226 care activities of feeding, herding, sheltering, or milking livestock, as well as assisting  
227 birth, butchering, or skinning, and disposal of aborted material, or consumption of raw  
228 milk. Factors evaluated for animal RVFV exposure were age and age class, sex, breed,

229 body condition, herd size, grazing strategy, and environmental conditions including  
230 proximity to water, local vegetation, rainfall, and mosquito control measures. Our data  
231 extraction tool was designed to capture factors related to the area the animal was raised  
232 (water sources nearby, mosquito exposures, rainfall, vegetation), herd factors (grazing  
233 strategy, mosquito control measures, herd size) and individual risk factors such as body  
234 condition and breed. In some animal studies, the age of the animal (by dental  
235 examination) and sex could be objectively assessed at the time of sampling. We  
236 grouped common animal exposures and determined how many studies had assessed  
237 for the risk factor and how many individual studies found statistically significant results  
238 by bivariate or multivariate analyses. Not all studies separated the species of animals  
239 involved within each exposure, and these have been reported as “not subdivided by  
240 species.” Information was recorded on the diagnostic tests used to identify acute cases  
241 or exposures, and on each study’s criteria used to identify suspected and confirmed  
242 animal or human cases of RVF. Available information regarding local RVF surveillance  
243 methods was noted, as well as any information about the RVFV lineage involved in the  
244 reported cases. Where individual outbreaks were reported in more than one publication  
245 or governmental bulletin, case numbers and mortality for that outbreak were taken from  
246 the latest reports.

247 **Study risk of bias assessment.** We used an abridged version of the Liverpool Quality  
248 Appraisal Tool (LQAT) [57, 58] to assess study quality and risk of bias of included  
249 studies because of the tool’s flexibility in accommodating different study designs and in  
250 creating potential bias assessments specific to our diverse set of studies. Scoring  
251 involved assessment of possible subject selection bias, response bias, follow up bias,

252 bias in risk factor assessment, bias in outcome assessment, or possible bias in  
253 reporting the outcome. Scoring also included whether the study's analysis involved  
254 adjustment for potential confounders. The LQAT score, combined with recorded  
255 information about study design and power, were used to classify reports as weak (score  
256 1-5), moderate (score 6-8), or strong evidence (score 9 or 10) regarding local risk for  
257 disease or exposures. Each study was assessed independently by two reviewers with  
258 discrepancies resolved in consultation with a third reader.

259 **Effect measures.** We enumerated the cumulative number of outbreaks reported within  
260 national and sub-national borders over time, and the observed incidence or period  
261 prevalence by location. However, because of significant heterogeneity created by  
262 reporting bias, relative risk comparisons among the multiple locations were considered  
263 unreliable. Continent-wide RVF risk assessment for Africa, based on climate, weather,  
264 population, and landscape factors has been recently well studied [59-64] and so was  
265 not repeated here. We have, however, updated prior meta-analysis assessment [65] of  
266 individual human risk factors to provide evidence regarding specific sub-groups who  
267 might serve as suitable high-risk subjects for a human vaccine trial. Because the  
268 chances of infection were based on post hoc determination of exposures, summary  
269 odds ratios derived by random effects statistical modeling were used to determine the  
270 strength of these associations in the meta-analysis.

271 **Synthesis methods.** Outbreaks and exposures were classified into five groups: 1)  
272 acute human RVF cases, 2) acute animal cases, 3) human RVFV exposure data (based  
273 on sero-surveys), 4) animal exposure data, and 5) arthropod infection data. These were  
274 tabulated over time and space using frequency measures and geo-located, when

275 necessary, using Google Earth Pro software (available at  
276 <https://www.google.com/earth/versions/>). The two decades of inclusion (1999-2010 and  
277 2001-2021) were assessed jointly and then separately to determine the evolution of  
278 disease, changes in detection of disease through improved diagnostics, and the effects  
279 of more robust surveillance. Regional maps at the national and sub-national level were  
280 then prepared using QGIS software (<https://www.qgis.org/en/site/>) using base maps  
281 supplied by the Database of Global Administrative Areas (GADM) (version 3.4, (April  
282 2018, [www.gadm.org/data](http://www.gadm.org/data), licensed for non-commercial purposes; see  
283 [www.gadm.org/license](http://www.gadm.org/license)). Surveillance systems in animals, humans, and vectors were  
284 categorized either as early warning systems, detection in hospital-based surveys, use of  
285 sentinel herds for surveillance, or farmer reported syndromic surveillance. For meta-  
286 analysis of individual human level risk factors, results from those included studies with  
287 relevant human exposure data were entered into Comprehensive Meta-Analysis  
288 software, v.3 (CMA, Biostat, Englewood, NJ) for calculation of pooled summary  
289 estimates of exposure effects, along with their confidence intervals. Heterogeneity  
290 levels were scored using Higgins's and Thompson's  $I^2$  statistic [66]. Summary estimates  
291 of intervention effects were computed using Der Simonian and Laird random-effects  
292 modeling [67] implemented by the CMA software. Summary data were presented  
293 visually by Forest plots showing the respective odds ratio and 95% confidence interval  
294 ( $CI_{95\%}$ ) for the pooled analysis. Assessment for potential publication bias was carried  
295 out by visual inspection of funnel plots, and statistically by calculating the Egger test. To  
296 explore heterogeneity and factors that could potentially modify the summary estimates  
297 of effect, we performed subgroup analyses stratified by study risk of bias, and by year of


298 publication. For the sensitivity analysis, each meta-analysis was retested with the  
299 exclusion of one study at a time to assess the possibility of a disproportionate impact of  
300 any individual study on summary estimates.

301

## 302 **Results**

### 303 **Studies and RVFV reports selected for inclusion**

304 Initial screening of online publication databases yielded 7097 listings for RVF or RVFV  
305 during the period January 1999-June 2021 for our initial review (Fig 1). These were  
306 supplemented by 771 georeferenced outbreak case reports obtained from OIE  
307 databases World Animal Health Information System (WAHIS,  
308 <https://wahis.oie.int/#/home>) for events after 2004, and from OIE Handistatus II  
309 (<https://web.oie.int/hs2/report.asp?lang=en>) for earlier 1999-2003 events. Other  
310 sources, including private archives, governmental reports, ProMed listings, listings from  
311 previous systematic reviews [65, 68], and non-indexed citations (found in Google  
312 Scholar and in bibliographies of papers under review), provided an additional 667  
313 reports for consideration for possible inclusion. After removal of duplicates, 1976 unique  
314 articles or reports were selected for full text review. After the full text review was  
315 performed, 285 events reported in 281 publications, plus the 771 events identified in  
316 OIE databases and 48 from grey literature, identified a total of 1104 unique human or  
317 animal RVFV transmission events for inclusion in the analysis.



318

319 **Fig 1. PRISMA systematic review flow diagram of data collection and evaluation**

320 Online searches for publications and data registers (left side flow) were supplemented  
321 by governmental outbreak reports, non-indexed citations found in local archives, and  
322 citations found within the reference lists of the papers that were reviewed (right side  
323 flow).

324

325 **Report characteristics**

326 Of the 285 included reports selected from the published literature, 91% were in peer-

327 reviewed journals, 7% were in governmental reports, and 2% were in abstracts or

328 published correspondence. Following the regional designations of the United Nations,

329 43% of these papers reported RVF activity in East Africa, 13% in West Africa, 13% in

330 the Arabian Peninsula, 10% in North Africa, and 10% in Southern Africa. The countries

331 of Kenya (n= 42 reports), Saudi Arabia (n= 32), Tanzania (n = 24), South Africa (n= 22),

332 Madagascar (n= 14), Sudan (n= 13), Mauritania (n= 11), and Mozambique (n= 11) were

333 the most frequent subjects of RVF outbreak reports and surveys. Thirty percent of

334 reports documented active epidemics/epizootics, 61% were exposure studies performed

335 during interepidemic periods, and 7% were post-epidemic survey studies. One hundred




336 sixty-five (58%) were cross-sectional surveys of humans or animals, 60 (21%) were  
337 acute case series, 35 (12%) involved prospective cohorts, and 4 (1%) were case-control  
338 studies. Forty-two (15%) reported on vector testing in affected areas. Among published  
339 studies, 195 (68%) were non-randomized, 79 (28%) involved some form of random  
340 sampling, and 11 (4%) did not clearly indicate how sampling was done. In terms of  
341 study quality, the median LQAT score for published studies (where higher scores  
342 indicated higher quality studies) was 6 (range = 2-11, IQR 5-7), meaning the majority of  
343 studies had moderate-to-high risk of bias in assessing risk by location or by sub-  
344 population. Details of all included studies, including individual risk-of-bias scores are  
345 provided in S2 Table.

#### 346 **Where RVFV transmission or RVF epidemics/epizootics occurred, 1999-2021**

347 Overall, 39 countries had evidence of RVFV circulation in humans, animals, or  
348 vectors during the 1999-2021 period, based on detection of probable or confirmed acute  
349 cases, positive PCR testing, or serosurvey results (Fig 2 and S4 Table). Eighty-three  
350 reports documented 124 locations in 19 countries that had 4,353 probable or confirmed  
351 acute human RVF cases and 755 deaths (Fig 3), whereas 107 reports documented  
352 acute RVF animal events (470 OIE confirmed cases) in 31 countries between 1999 and  
353 2021 (Fig 4). The median year of reported events was 2010. Outbreaks of clinical  
354 disease among humans or animals occurred at average rates of 5.8/year and 12.4/year,  
355 respectively, with Mauritania, Madagascar, Kenya, South Africa, and Sudan having the  
356 most human outbreak years. When month of onset was given for active epizootics or  
357 epidemics, in East Africa, 77% (27/35) of outbreaks began between November and  
358 January; for southern Africa, 80% (8/10) began between March and June; for West



359 Africa, 92% (12/13) began between July and October; for the Arabian Peninsula, 93%  
360 (13/14) began between August and October; and for North Africa, 67% (6/9) began  
361 between September and October.




362

363 **Fig 2. Regional map of countries exposed to RVFV infection based on findings of**  
364 **studies included in the systematic review.** Countries were categorized as to whether  
365 there was evidence of human, animal, or arthropod RVFV infection during the 1999-  
366 2021 era. Base map is from Database of Global Administrative Areas (GADM) (version  
367 3.4, (April 2018, [www.gadm.org/data.html](http://www.gadm.org/data.html))  
368

369 Maps in Figs 3 and 4 show the sub-national administrative regions where acute  
370 human and animal cases were reported during the earlier (1999-2010) or latter (2011-  
371 2021) halves of our study period, or both. The countries with multiple repeated human  
372 outbreaks across both early and later time intervals were Kenya (n=4), Mauritania (n=5),


373 South Africa (n= 4) and Madagascar (n= 2). S5 Table lists dates, place names, GPS  
374 locations, reported human case counts, incidence rates per 100,000, reported numbers  
375 of deaths, and estimated case fatality risks.



376

377 **Fig 3. Sub-national administrative regions experiencing acute human cases of**  
378 **RVF during the years 1999-2021** Locations are shaded according to whether they  
379 experienced outbreaks before or after 2011, or if they had outbreaks during both  
380 periods. Base map is from Database of Global Administrative Areas (GADM) (version  
381 3.4, (April 2018, [www.gadm.org/data.html](http://www.gadm.org/data.html))  
382

383 In terms of epizootic activity, Fig 4 highlights the countries that experienced repeated  
384 acute RVF outbreaks among animals during one or both decades of the 1999-2021  
385 period. These were Kenya (n= 4), Madagascar (n= 2), Mauritania (n= 6), Mayotte (n=  
386 2), Mozambique (n=2), Senegal (n=3), and South Africa (n=4).



387

388 **Fig 4. Sub-national administrative regions experiencing acute animal cases of**  
389 **RVF during the years 1999-2021** Locations are shaded according to whether they  
390 experienced outbreaks before or after 2011, or during both periods of time. Base map is  
391 from Database of Global Administrative Areas (GADM) (version 3.4, (April 2018,  
392 [www.gadm.org/data.html](http://www.gadm.org/data.html))  
393

393

#### 394 **Serosurveys of human and animal RVFV exposure**

395 Of the population surveys performed during interepidemic periods to detect  
396 evidence of prior local RVFV circulation, 50 surveyed human populations, 79 surveyed  
397 livestock populations, and 23 tested local wild animals. Of these, eight jointly surveyed  
398 both humans and livestock, and nine surveyed both wildlife and livestock. A summary of  
399 available diagnostic assays used to identify anti-RVFV antibodies is presented below in  
400 Table 1.

401

402

403 **Table 1. Currently used serologic assays for detection of RVFV exposure in**  
 404 **humans.**

<b><i>In-house Methods</i></b>			
<b>Method</b>	<b>Publication</b>	<b>Target antibody</b>	<b>Brief description</b>
ELISA <sup>1</sup>	LaBeaud et al. 2008 [69]	IgG	Indirect ELISA for presence of anti-RVFV IgG antibodies at Stanford University School of Medicine using inactivated MP-12 strain for coating antigen. Validated in humans
ELISA DIVA <sup>1,2</sup>	McElroy et al. 2009 [70]	IgM or IgG	Two parallel ELISA to distinguish naturally infected from vaccination. Validated in goat and humans. Does not distinguish IgG vs IgM
ELISA <sup>1</sup>	Paweska et al. 2005 [71]	IgM and IgG	IgG sandwich and IgM capture assay that uses irradiated whole virus for antigen. Validated in humans
ELISA <sup>1</sup>	Paweska et al. 2007 [72]	IgG	Antigen made using recombinant N protein. Validated in humans
ELISA <sup>1</sup>	Jansen Van Vuren and Paweska, 2009 [73]	IgM and IgG	Indirect ELISA for IgG and IgM separately. Antigen made using recombinant N protein. Validated in humans
VNT <sup>3</sup>	Winchger Schreur et al. 2017 [74]	All neutralizing antibodies	Uses a virulent RVFV that expresses enhanced green fluorescent protein. Not species specific
Optical Fiber Infrasond Sensor	Sobarzo et al. 2007 [75]	IgG	Sandwich based ELISA and antigens are immobilized on an optical fiber that makes it more sensitive. Validated in humans
Luminex DIVA <sup>2</sup>	Van der Wal et al. 2012 [76]	IgM and IgG	Bead based assay that detects RVFV Gn and N proteins
<b><i>Commercially available methods</i></b>			
	<b>Manufacturer</b>		
IFA <sup>4</sup>	EUROIMMUN	IgG	Approved for clinical testing
IFA <sup>4</sup>	EUROIMMUN	IgM	Approved for clinical testing
ELISA <sup>1</sup>	Biological Diagnostic Supplies Limited	IgM and IgG	Approved for clinical testing
ELISA <sup>1</sup>	ID-Vet	IgG	Competitive ELISA kit for the detection of anti-RVFV antibodies in serum or plasma. Multi-species that includes human validation

ELISA <sup>1</sup>	ID-Vet	IgM	IgM Antibody Capture ELISA for the detection of anti-nucleoprotein IgM antibodies. Validated for ruminant serum and plasma
--------------------	--------	-----	--

405 <sup>1</sup>ELISA: enzyme-linked immunoassay <sup>2</sup>DIVA: Differentiating Infected from Vaccinated  
406 Animals <sup>3</sup>VNT: Viral neutralization test; <sup>4</sup>IFA: immunofluorescent antibody  
407 *Adapted from Petrova, et al., BMJ Glob Health 2020,doi:10.1136/bmjgh-2020-002694*  
408 *[77] under Creative Commons CC BY-NC*  
409

410 In several animal surveys performed during interepidemic periods, low rates of  
411 livestock and wildlife anti-RVFPV IgM seropositivity or IgG seroconversion were detected  
412 in areas of Namibia, Senegal, South Africa, and Kenya [47, 78-80] suggesting  
413 unsuspected ongoing RVFPV transmission in those locations without detection of  
414 concurrent clinical RVF cases. Also of note were animal studies that showed serologic  
415 evidence of RVFPV circulation among animals or humans within areas that had no prior  
416 evidence of RVFPV circulation. These were, among animals only, in Libya [OIE], Tunisia  
417 [81], and Western Sahara [82] in North Africa; but in either humans or animals, in Sierra  
418 Leone [36], Côte d'Ivoire [83], Djibouti [84], Rwanda [85, 86], and eSwatini [OIE], i.e.,  
419 geographical areas in sub-Saharan Africa with no previously documented transmission.  
420 Anti-RVFPV antibody testing of human patients in health centers in Ghana [87] and  
421 Jordan [56] did not detect evidence of local exposure.

#### 422 **RVFPV lineage studies**

423 Twenty-six papers reported on sequence analysis of RVFPV isolates from recent  
424 and more distant outbreaks in an attempt to identify the geographic extent of specific  
425 viral lineages in circulation at the time. Although variants have been seen to cluster in  
426 East African, West African, and Southern African groupings, the results from different  
427 studies are heterogeneous, and nomenclature for these variants has not yet been  
428 standardized. The included studies on strain and lineage are summarized in S6 Table.



429 Differences are noted depending on the segment(s) of the viral genome analyzed, the  
430 clustering algorithm used, and the reference isolate used as a 'type specimen' for  
431 comparison.

432 Sub-lineages of the Eastern group were found in the 1997-1998 Kenya/Tanzania  
433 RVF outbreak, as well as the 2000-2001 Saudi Arabia/Yemen outbreak [88, 89]. These  
434 were most similar to the RVFV isolates from humans, animals, and insects during the  
435 Kenya 2006-2007 epidemic (when variants termed Kenya-1, Kenya-2, and Tanzania-1  
436 co-circulated) [88, 90]. Later 2008-2009 isolates from outbreaks in Comoros [91],  
437 Mayotte, and Madagascar [92, 93] were also from the Eastern group. Although Eastern  
438 African group isolates were recovered from Mauritania in 2010 [94] and Senegal in 2013  
439 [95] in West Africa, outbreaks in these countries in other years have identified a  
440 separate West African lineage grouping of RVFV isolates [96, 97]. Grobbelaar and  
441 colleagues [98] have used the sequence from the viral Gn surface peptide to compare  
442 198 isolates recovered between 1944-2010 from across Africa and the Arabian  
443 Peninsula, and have defined 15 different lineages, which they have labeled A through  
444 O. South African isolates in 2008 were grouped in the C lineage, related to the Kenya-1  
445 lineage. However, during 2009-2011, South African isolates were predominantly found  
446 in a new, separate lineage H [99], while one isolate in Northern Cape Province was from  
447 lineage K. Lineage K was later identified in a small South African outbreak in 2018  
448 [100], and in an RVFV-infected Chinese expatriate working in Angola in 2016 [101].

449 **Table 2. Rift Valley fever virus lineage determinations for isolates recovered in**  
450 **recent epidemics, based on cluster analysis of gene sequences for the viral Gn**  
451 **surface protein.** (Based on Grobbelaar, et al. 2011 [98])  
452

Grouping	Grobbelaar System	Year	Country	Species	Lineage Notes	Reference
<b>East African</b>	lineage C	2000-01	Saudi Arabia, Yemen	Human	Very similar to 1997-98 isolates/variants Kenya-1, Kenya-2, and Tanzania-1	[88, 89]
	lineage C	2006-07	Kenya	Humans, Livestock, Vectors		[88, 90]
	N/A	2007	Comoros	Humans	Similar to Kenya 2006-7	[91]
	lineage C		Madagascar			[92, 93]
<b>West African</b>			Mauritania, Senegal, Niger		Related to Kenya-1 lineage	[96, 97]
<b>Southern African</b>	lineage C	2008-09	South Africa			[98]
	lineage H	2009-11	South Africa			[102]
	lineage K	2009-11	South Africa			[102]
	lineage K	2018	South Africa			[100]
	lineage K	2016	Angola/China			[101]

453


#### 454 **Human outbreak characteristics**

455 During human outbreaks, surveillance and reporting efforts varied greatly from  
 456 location to location. We observed that among human outbreak reports, the calculated  
 457 incidence rates of probable or confirmed human RVFV infections among local or  
 458 regional residents varied between 0.01 and 91 per 100,000 population, with a median  
 459 value of 2.5. Case fatality risks for these probable or confirmed cases varied from zero  
 460 to 65% (median = 14.3%) in locations where more than one case was reported (n= 107  
 461 locations from 41 publications, see S5 Table).

462 The cumulative human exposure to RVFV infection is also heterogeneous across  
 463 locations. In endemic areas, this cumulative exposure is usually estimated from cross-  
 464 sectional surveys based on the population prevalence of human anti-RVFV IgG

465 seropositivity at different ages. Among the 25 well-designed population-based  
466 serosurveys (scored as having low risk-of-bias) among our included reports (n= 44), IgG  
467 seroprevalence during interepidemic periods ranged from (0.15%) in Madagascar in  
468 2014-2015 [40] to 22% in eastern Kenya in early 2006 [103] and again in 2013-2014  
469 [104], with an overall median intra-epidemic value of 5.2% (IQR 1.8% - 13%)  
470 seropositivity across all 25 surveys.

471  
472



473


474 **Fig 5. Acute human RVF events per year during 1999-2021, by geographic regions**  
475 **across Africa, the Indian Ocean, and the Arabian Peninsula**

476 Acute human RVF outbreaks were reported across Africa, the Arabian Peninsula, and  
477 the Indian Ocean from 2000-2021 (Fig 5). The highest number of reported human RVF  
478 events occurred in 2006-7, starting in East Africa, moving to Sudan (North Africa) and



479 then to the islands in the Indian Ocean during 2007-2008, as part of an evolving  
480 epidemic and epizootic of the East African RVFV lineage. In East Africa, new RVFV  
481 outbreaks have recurred annually since 2016, whereas no new human cases have been  
482 reported in the Arabian Peninsula since 2001. RVF flared in southern Africa in multiple  
483 episodes between 2008 and 2011 and West African countries Mauritania and/or  
484 Senegal have reported cases across multiple years, 2003, 2010, 2012-3, 2015-6, and  
485 again in 2020.  
486

487



488

489 **Fig 6. Acute animal RVF events per year during 1999-2021, by geographic regions**  
490 **across Africa, the Indian Ocean, and the Arabian Peninsula**

491

492 A larger number of acute animal RVF events (N = 273), compared to human events (N  
493 = 132), was reported during the 1999-2021 period studied. The reported animal events  
494 in southern Africa (N= 31) and in the Indian Ocean islands (N= 19) were concentrated  
495 during the 2008-2011 period (Fig 6). By contrast, animal events in West Africa and East  
496 Africa were reported during most years of the targeted time interval (cumulative N= 80  
497 and N=118, respectively), with the highest yearly tally being 41 reported events in 2018  
498 (Fig 6). No animal event was reported in the Arabian Peninsula after 2010, while only a  
499 low number of events were reported in Central and North African countries between  
500 2002-2019 (cumulative N= 8 and N= 9, respectively; Fig. 6).


501 Of 28 papers that reported both human and livestock data, 17 contained  
502 information on concurrent co-local RVF epidemic and epizootic activity. These reports  
503 documented combined human/animal RVFV transmission events in Saudi Arabia [105,  
504 106] and Yemen [107] in 2000-2001; in Egypt [108] and Mauritania [109] in 2003; in  
505 Kenya [5, 90] and Tanzania [90, 110] in 2006-2007; in Mauritania in 2010 [94, 111] and  
506 again in 2012 [112]; in Senegal in 2013-2014 [95]; in Niger [97] and in Uganda [113] in  
507 2016; and in Kenya [114] , Mayotte [115], and South Africa [116] in 2018.

508 **Evidence of vector presence and competence for interepidemic RVFV**  
509 **transmission.** In S7 Table we summarize 31 published studies from 1999-2021 that  
510 tested arthropod vector species for RVFV infection potential. Our systematic review  
511 identified 21 locations (in 8 countries) with RVFV-positive vectors, including mosquitos  
512 from *Aedes*, *Culex*, *Anopheles*, and *Mansonia* spp. and from *Hyalomma* spp. ticks (Fig.  
513 2). Notably, in 6 out of 10 trapping surveys performed during interepidemic years in  
514 endemic zones, live RVFV or RVFV RNA was detected in captured vector mosquitoes  
515 or ticks [117-122]. As the lifespan of mosquito vectors is relatively short, the presence of  
516 RVFV viral RNA in these vectors likely represents sustained circulation in each of the  
517 given locations.

518 **Human risk of RVFV-related disease.** Among our included studies from the  
519 systematic review, 84 reports assessed human risk factors for RVFV exposure. The  
520 factors most commonly assessed were occupation (N= 33 papers), gender (N= 30), age  
521 (N= 89), contact with animals (N= 38), travel (N= 15), as well as proxies for mosquito  
522 exposure such as work or residence in proximity to water sources (N= 12), and personal  
523 behaviors related to mosquito avoidance (N= 29).

524 Quantitative assessment of the role of gender involved estimation of chances for  
 525 RVFV exposure by men and women in endemic settings. There were 31 studies that  
 526 reported RVFV exposure (cases or anti RVFV seropositivity) according to gender (Fig  
 527 7). There was moderate heterogeneity among these studies ( $I^2 = 39\%$ ), and random  
 528 effects modeling estimation yielded a summary pooled OR estimate of 1.41 (CI<sub>95%</sub> 1.24,  
 529 1.60,  $p < 0.001$ ) for males vs. females in their exposure rates (Fig 7). This value, based  
 530 on studies from 1999-2021, remained very similar to that calculated by Nicholas and  
 531 colleagues [65] (OR = 1.36) in their meta-analysis of studies from 1984-2011.

## Male:Female Odds Ratio for Human RVFV Infection




532

533 **Fig 7 Meta-analysis of the impact of human gender on odds of RVFV exposure in**  
 534 **at-risk populations**

535

536 **Greater human risk associated with animal contact.** Eleven well-structured  
537 human surveys (having moderate to low risk of bias, i.e., LQAT scores  $\geq 6$ ) compared  
538 rates of RVFV exposure among local residents according to the extent of their daily  
539 contact with animals, particularly ruminant livestock. Heterogeneity was high among  
540 these studies ( $I^2 = 68\%$ ). However, random effects meta-analysis, summarized in the  
541 Forest plot in Fig 8, yielded a summary OR estimate signifying a 46% increase in the  
542 odds of RVFV exposure among people with regular animal exposure (random effects  
543 model pooled OR = 1.46,  $CI_{95\%} = 1.09, 1.94$ ,  $p = 0.01$ ) in at risk populations. In separate  
544 task analyses, S1-S3 Figures show Forest plots for summary estimates of associations  
545 between butchering, sheltering, and milking livestock activities and risk of RVFV  
546 exposure among at-risk populations. The estimates were: for butchering, OR = 3.7  
547 ( $CI_{95\%} = 2.5, 5.4$ ,  $p < 0.001$ ,  $I^2 = 75\%$ ); for sheltering, OR = 3.4 ( $CI_{95\%} = 2.1, 5.4$ ,  $p <$   
548  $0.001$ ,  $I^2 = 57\%$ ); and for milking, OR = 5.0 ( $CI_{95\%} = 2.8, 8.8$ ,  $p < 0.001$ ,  $I^2 = 77\%$ ),  
549 indicating significantly higher risk with these exposures. Among these pooled studies,  
550 there was no evidence of publication bias (by funnel plot or by Egger's statistic). There  
551 were no yearly trends in exposure effects, nor did sensitivity analysis indicate evidence  
552 of any single dominant study for each exposure-related outcome.


## Odds Ratio of RVFV Infection When Exposed to Animals



553

554 **Fig 8 Meta-analysis of the impact of animal exposure on odds of RVFV exposure**  
 555 **in at-risk populations.**

## Odds Ratio of RVFV Infection When Handling Abortus



556

557

558 **Fig 9 Meta-analysis of the impact of handling RVF-related animal abortions on**  
 559 **odds of human RVFV exposure in at-risk populations**

560  
561           Thirty-nine included studies assessed human RVFV-infection risk factors related  
562 to different animal exposures and 17 of those studies linked animal exposures to acute  
563 human RVFV infections (S8 Table). In meta-analyses performed according to specific  
564 animal contact tasks, handling aborted material during an RVF outbreak had a pooled  
565 odds ratio of human infection (random effects model pooled OR = 3.65, CI<sub>95%</sub> = 2.32,  
566 5.73,  $p < 0.001$ ,  $I^2 = 73\%$ ).

567           Our survey also provided individual reports of an additional 21 significant animal  
568 contact risk factors that had not been commonly assessed. In a study in Tanzania  
569 during the 2006-2007 East Africa outbreak, 40% of 115 RVFV cases reported having  
570 contact with animal products including meat and milk from sick animals, compared to  
571 just 28% of the cases reporting having slaughtered an animal [123]. Specifically,  
572 consumption of meat from sick animals was associated with a nearly four-fold increased  
573 risk of RVF-associated death during the 2006-7 outbreak in Kenya [68].

#### 574           **Occupational and socioeconomic factors associated with RVFV exposure.**

575           Our systematic review identified seven studies overall that found statistically significant  
576 risks related to socioeconomic factors such as education level, ethnicity, and household  
577 size. Briefly, the less wealthy and less educated were overrepresented among RVFV  
578 exposed people (S9 Table).

579           Forty-five of the 506 papers assessed occupation as a human risk factor and 14  
580 references found occupation to be a statistically significant factor (S10 Table). For  
581 clarification, those who were classified as ‘herders’ may not necessarily live a pastoralist  
582 lifestyle, so they have been given separate status. We found three studies that reported

583 high seroprevalence among “housewives”, which might be explained by their frequent  
584 handling of raw meat and animal products for cooking.

585 **Risk Factors for RVF severity.** Out of the 135 included papers assessing  
586 human RVFV exposure and disease, 12 presented data on human risk factors  
587 associated with more severe RVF disease presentation (S8 Table). Persons with severe  
588 disease were usually more likely to have had animal contact, [21, 124, 125]. In  
589 outbreaks in Kenya [124, 125], specific animal contact activities such as handling or  
590 consuming products from obviously sick animals (OR for more severe disease = 2.53,  
591  $CI_{95\%} = 1.78, 3.61$ , population attributable risk percentage [PAR%] = 19%) and touching  
592 an aborted animal fetus (OR = 3.83,  $CI_{95\%} = 1.68, 9.07$ , PAR% = 14) were strongly  
593 linked to risk of severe (rather than mild) human RVF disease. Older age and death of a  
594 family member were also linked to more severe human disease [124]. In Sudan, males  
595 aged 15-29 years were overrepresented among patients who presented with severe  
596 disease, as compared to females of the same age [126]. Environmental factors, such as  
597 excess rainfall and muddy soil linked to emergence of mosquito blooms have also been  
598 linked to severe human disease in both Sudan and Kenya [127, 128].

599 Severity of human RVF was associated with the presence of concomitant co-  
600 infections. A fatal outcome in a travel related case was attributed to the presence of  
601 concurrent hepatitis A virus infection [45]. Additionally, a study in South Africa during the  
602 2010 RVFV outbreak indicated that existing HIV-positive infection status was associated  
603 with risk of the encephalitic form of RVF disease [129], a finding similar to experience  
604 among HIV-infected patients in Tanzania in 2007, where all patients with HIV-positive  
605 status developed encephalitis, and of whom 75% died [123].



606 Four studies performed in three countries (Kenya, Sudan, Saudi Arabia),  
607 examined the risk factors linked to death from RVF. In Kenya in 2007, consuming and  
608 handling products from sick animals and village and district location were linked to risk  
609 of death (OR = 3.67, CI<sub>95%</sub> = 1.07, 12.64, PAR% = 47%) [125, 130]. In Saudi Arabia, a  
610 retrospective analysis of the 2000-2001 outbreak showed that specific clinical signs  
611 were independently linked to death. These included jaundice, bleeding, and neurologic  
612 symptoms (P < 0.0002) [131]. One study demonstrated an increased level of RVFV  
613 replication in fatal RVFV [132].

614 **Risk factors for animal RVFV outbreaks.** Because human risk of RVFV  
615 exposure is closely associated with the local presence of infected livestock, we  
616 reviewed factors related to animals' risk of RVFV infection.

617 *Herd Immunity Levels.* Our systematic review included results from 174 animal  
618 studies, in which 144 tested domestic livestock and 26 tested wild animals for RVFV  
619 exposure and/or acute infection. Of all livestock studies included, 32 were conducted  
620 during an active epizootic, 10 were conducted just after an outbreak in the post-  
621 epidemic phase, and 97 were conducted during interepidemic years. For wildlife  
622 surveys, 5 were carried out during an active epizootic, 5 were done in the post-epidemic  
623 phase, and 14 were performed during interepidemic periods. Of all animal risk factors,  
624 sex and age were the most studied, and older animals and those that had lived through  
625 outbreaks were more likely to have been exposed. A wide range of anti-RVFV IgG  
626 seroprevalence was observed among livestock in endemic countries (4% in Senegal  
627 [95] to 39% in Tanzania [133]) and rates were dependent on species and population  
628 sampled, the timing of sampling, and the sampling strategy used. As a result,

629 seroprevalence listed at a given time and place did not imply a specific level of long-  
630 term herd immunity. A summary of livestock risk factors is presented in S11 Table.

631 *Herd Level Risks.* For herd level risks, the observed effects of herd size has  
632 varied across studies. A 2013-2014 study in a high risk area of Kenya showed that  
633 medium sized herds of 50-100 animals had a significantly higher seroprevalence  
634 compared to small herds (< 50 animal) or very large herds (>100 animals) [134], though  
635 this did not account for the differences in animal rearing strategies dependent on herd  
636 size. The statistical significance of herd size was lost when village was accounted for as  
637 a random effect [74]. In Tunisia, the first assessment of serology in camels in 2017-  
638 2018 showed that camels living in smaller herds intended for meat production had a  
639 higher seroprevalence than those used for military purposes or tourism. Additionally,  
640 this study found that camels that had contact with ruminants had significantly higher  
641 rates of RVFV exposure [81].

642 The differing levels of RVFV susceptibility across livestock species (S11 table)  
643 further complicates the herd immunity threshold related to animal-to-human RVFV  
644 spillover. Additionally, livestock had variable contact with other livestock from  
645 neighboring herds and regions. An extensive social contact analysis from the 2008-  
646 2009 Madagascar outbreak showed that bartering practices, in which cattle can have  
647 multiple contacts within a village, was a significant seroconversion risk factor [135].  
648 Such bartering practice can support inter-village RVFV circulation, whereas formal trade  
649 networks or cross-border smuggling were more likely to be responsible for trans-  
650 national and international spread [136, 137].

651 *Individual Animal Risks.* For individual-level animal risk, studies examining cattle  
652 had the most significant findings. Abortion was the most recognized clinical sign  
653 associated with RVFV infection and recent abortion was significantly associated with  
654 RVFV exposure [138]. This experience was the first to identify the 2018 RVFV  
655 outbreaks in Kenya when farmer-reported surveillance was implemented [127]. None of  
656 the included studies found an association between underlying animal body condition  
657 and RVF risk.

658 **Wild animals' role in RVFV transmission.** RVFV has been found in a variety of  
659 wild mammals [48]. Their role in transmission to humans has been documented, as well  
660 as their role as viral amplifiers that contribute to increased risk of livestock infection.  
661 Wild ruminants, especially buffalo, have been found to have significant herd  
662 seroprevalence during inter-epidemic period in endemic areas [46, 139, 140]. For  
663 species-specific risk factors, interspecific network centrality, home range and  
664 reproductive life-history traits were associated with RVFV occurrence. S12 Table  
665 summarizes the wild animal seropositivity and acute infections identified in our literature  
666 review.

667 **Animal Vaccination.** Among the included papers in this review, we identified 17  
668 studies in six countries that included vaccinated animals. Countries that had vaccinated  
669 cattle, sheep, or goats for RVFV were Kenya, Tanzania, South Africa, Egypt, and Saudi  
670 Arabia [5, 141-145]. In Egypt, between 2013 and 2015, seroprevalence of anti-RVFV  
671 was 14.9% among immunized cattle, compared to 7.9% among unimmunized cattle  
672 [146]. Although livestock are required to be vaccinated before they are exported to  
673 Saudi Arabia, a study at a livestock quarantine facility in Djibouti found an anti-RVFV


674 IgM-positive seroprevalence of 1.2% in sheep and goats (small ruminants grouped as  
675 'shoats') and 0.3% in cattle [141, 147]. A 2009 study in Mecca, Saudi Arabia found  
676 55.8% anti-RVSV IgG in ostensibly vaccinated sheep, but still found a 2.6% rate of IgM  
677 positivity, indicating possible ongoing circulation (despite herd vaccine status) or recent  
678 vaccination [148].

679 **Additional considerations for RVF risks.** The range of RVFV-endemic areas is  
680 expanding, and the virus appears to travel well [39, 149, 150]. In endemic countries,  
681 internal travel to or from outbreak epicenters is typically included in suspect case  
682 definitions. A recent review by Grossi-Soyster and LaBeaud [151] has highlighted the  
683 risk of RVFV transmission to travelers, and although most travelers will not have direct  
684 contact with livestock, their mosquito exposure behavior needs to be assessed.

685 **Reported surveillance methods** in animal, humans or vectors are summarized  
686 in S13 Table. Our review revealed 52 papers specifically reporting on RVFV  
687 surveillance. Their methods are not uniformly implemented, but include: i) leveraged  
688 RVFV testing of samples taken during surveillance for other diseases such as malaria,  
689 dengue, HIV, or Lassa fever [38, 152-154]; ii) the use of sentinel livestock herds in high-  
690 risk areas; iii) increased case surveillance based on monitoring of weather-related early  
691 warning signs; and iv) international collaborations with neighboring regions to conduct  
692 surveillance. These surveillance systems do not necessarily operate in parallel, but  
693 instead may overlap and may only be implemented at times of perceived increased risk.

694 Fig 10 depicts the different types of early warning and surveillance systems and  
695 their relative certainty. S13 table further summarizes available information from open-

696 source platforms on the early warning and surveillance systems used for RVFV  
697 transmission during 1999-2021.



698 **Fig 10 Progressive scale of surveillance that can used to indicate an impending**  
699 **RVFV disease outbreak**  
700 *Republished with permission of The National Academies Press, from Under the*  
701 *Weather: Climate, Ecosystems, and Infectious Disease (2001), Chapter 7: Towards the*  
702 *Development of Disease Early Warning Systems. P. 87; permission conveyed through*  
703 *Copyright Clearance Center, Inc. under license ID #1142222*  
704

705  
706 **RVFV Diagnostics.** When implementing surveillance for detecting RVFV  
707 transmission, one major constraint is the limited availability of accurate diagnostics in  
708 places where RVF disease occurs. For both human and animals, reliance on a clinical  
709 presentation to prioritize RVFV testing is complicated by the significant clinical  
710 diagnostic overlap with other febrile infection syndromes.

711 Although detection of circulating RVFV RNA by RT-PCR can be a definitive  
712 diagnosis of active infection, because the human and livestock viremic period is typically  
713 only 4-6 days (up to 14 days if hemorrhagic human disease), serologic testing is more  
714 extensively used to investigate the epidemiology of recent and past infection. We

715 extracted data from 207 included review reports on the type of assays recently  
716 employed for diagnosis of acute RVF. No studies tested livestock and wild animals  
717 together for acute infection. The assays used to detect acute RVFV infections are  
718 summarized in Table 3.

719

720 **Table 3: Summary of acute diagnostic assays employed in included studies, by**  
721 **species**

Number of Included Studies that Used the Following Methods for Detection of Acute RVFV Infection												
Species	IgM	IgM, direct <sup>1</sup>	IgM, PCR	IgM, PCR, direct <sup>1</sup>	IgM, PCR IgG SC <sup>2</sup>	IgM, IgG SC <sup>2</sup>	PCR IgG SC <sup>2</sup>	Direct <sup>1</sup> only	PCR only	PCR, direct <sup>1</sup>	IgG SC <sup>2</sup> only	Total
Livestock	26	0	4	0	1	3	2	0	5	0	3	44
Humans	21	2	23	4	2	0	0	2	9	1	0	64
Humans, livestock	1	1	5	3	1	0	0	0	1	0	0	12
Humans, livestock, wildlife	0	0	0	1	0	0	0	0	0	0	0	2
Wildlife	0	0	1	0	0	0	0	1	0	1	1	4
Method Total	48	3	33	8	4	3		3	15	2	4	

722 <sup>1</sup>Direct: Direct detection methods include immunofluorescence assay, cell culture (virus  
723 isolation), electron microscopy, and immunohistochemistry

724 <sup>2</sup>SC: IgG Seroconversion of IgG (positive IgG during the study period AND a previously  
725 documented negative status from the same individual)

726

727

728

## 729 **DISCUSSION**

730 During RVF epidemics, assessment of incidence, prevalence, and associated  
731 risk factors for infection are often based on case series of suspected patients, rather  
732 than well-designed, population-based surveys that enumerate laboratory-confirmed

733 cases vs. non-cases. Epidemic and epizootic outbreak surveys are further hampered by  
734 limited access to the affected rural communities, which are often experiencing severe  
735 flooding caused by excessive rainfall, and very limited access to diagnostic testing. In  
736 addition, survey incidence/prevalence calculations may be imprecise because of lack of  
737 accurate census information. As a result of these factors and the irregular frequency of  
738 disease outbreaks, the epidemiology of RVFV transmission and the risk factors for  
739 RVFV-related human disease are not well defined. In some endemic areas, post-  
740 epidemic serosurveys have shown high community exposure to RVFV [69, 104, 153-  
741 158], even though symptomatic RVF had been only rarely reported by local health care  
742 services. Based on our consolidated picture of recent RVFV epidemiology and the  
743 knowledge gaps we have identified, future operational research and clinical trial design  
744 should consider the factors discussed below, with the understanding that currently  
745 available data have some significant limitations in accurately defining human risk for  
746 RVF.

747 Our review indicated that during the last two decades, new patterns of RVF  
748 epidemiology have emerged. The virus continues to expand its range across Africa  
749 countries and into new regions within endemic countries [59, 159]. It should be noted  
750 that among studies that were technically excluded from our review, there were several  
751 completely negative serosurveys of animals performed in Spain [52], the Canary Islands  
752 [53], Mauritius [160], Zanzibar [161], South Korea [55], and Poland [54]. Expansion of  
753 RVFV transmission has been aided by livestock movement [34, 162-165] and the  
754 increasing frequency of extreme weather events involving heavy rainfall and flooding  
755 [60]. The discovery of vertical transmission within arthropod vector species other than

756 floodwater *Aedes* spp. mosquitoes [166] indicates the existence of multiple pathways for  
757 local RVFV persistence in different ecosystems during time periods that are in between  
758 recognized outbreaks. An additional non-vector route of RVFV transmission to humans,  
759 i.e., maternal-fetal transmission, has also been identified recently [167-169], and it has  
760 been established that RVFV can be an abortifacient in humans [170]. Thus, treating  
761 RVF as a concern only during large scale outbreaks in known hotspots fails to capture  
762 the full burden of disease and its underlying transmission, and fails to detect new areas  
763 of emergence.

764 The review identified 9 actionable critical knowledge gaps for vaccine  
765 development and testing. Until this knowledge is improved, clinical trial planning and  
766 therefore vaccine development will continue to face practical implementation challenges  
767 that can't easily be overcome:

- 768 1. Gap 1: Defining the likely interval between significant RVF outbreaks is  
769 challenging
- 770 2. Gap 2: The unpredictability of livestock herd immunity
- 771 3. Gap 3: Differences in seasonality across endemic/enzootic locations.
- 772 4. Gap 4: Data challenges related to bias based on limited study designs and  
773 inconsistent reporting.
- 774 5. Gap 5: Delineating human risk factors.
- 775 6. Gap 6: Need for consistent naming of RVFV lineages and strains.
- 776 7. Gap 7: Need for consistent RVFV testing frameworks.
- 777 8. Gap 8: Evolving better approaches to diagnostics.



778 9. Gap 9: The need for One Health approaches for RVFV detection and  
779 control.

780 **Gap 1: Defining the likely interval between significant RVF outbreaks is**

781 **challenging** The limited understanding of transmission persistence during  
782 interepidemic periods is a major gap affecting our ability to control continued expansion  
783 of RVFV, both within and between countries. Prospective studies during interepidemic  
784 periods are needed to provide a deeper understanding of how RVFV survives then  
785 subsequently thrives in an endemic area. Study findings could then suggest how  
786 mitigation efforts, such as vaccination of high-risk humans, can be implemented even  
787 before existing surveillance systems detect an outbreak.

788 Defining periodicity of outbreaks is challenging because, without active case  
789 finding, passive detection is an imperfect, trailing indicator of transmission, as it requires  
790 a large enough case number of RVF clinical syndromes (e.g., abortions in livestock) to  
791 identify events. Over the last two decades, increased availability and sensitivity of RVFV  
792 diagnostic assays, including genotyping, have contributed to increased recognition of  
793 viral transmission. However, without baseline interepidemic surveys in both high and  
794 low risk areas it is not possible to determine whether RVF outbreak waves are due to  
795 persistence or to re-introduction of RVFV transmission. As the outbreak intervals for  
796 RVFV remain undefined, the lack of studies during interepidemic periods limit our ability  
797 to understand viral maintenance and make it difficult to qualify endemicity in support of  
798 mitigation efforts such as vaccination. More useful data would include concomitant  
799 active surveillance of vectors, livestock, and humans, and information on rainfall,  
800 temperature, mosquito larval sources, and the frequency of risk-related human

801 behaviors. Because RVF livestock outbreaks are up to five times more likely to occur  
802 where outbreaks have previously occurred, and human outbreaks are more likely to  
803 occur in the same locations as livestock outbreaks [5, 171], areas with prior RVFV  
804 transmission shown in Figs. 3 and 4 would be best locations to characterize  
805 interepidemic transmission.

806 Kenya, South Africa, Madagascar, and Mauritania have had recurrent human  
807 and domestic animal RVF outbreaks in the last two decades and are thus most likely to  
808 experience additional outbreaks in the near future, and thus could be most suitable for a  
809 human vaccination trial. Notably, areas with recurrent outbreaks tend to have more  
810 robust surveillance which may account for the higher frequency of RVF detection in  
811 those locations (i.e., ascertainment bias). This could impact the predictability of  
812 outbreaks, and strongly affect the validity of vaccine trial endpoints. Based on findings  
813 identified in this systematic review, RVF can be more likely in a given location,  
814 compared to a similar nearby location due to many factors, including the total number of  
815 susceptible hosts (influenced by herd immunity), the presence of wildlife reservoirs  
816 [172], the water retention properties of the soil and rainfall patterns [63], local cultural  
817 practices that may increase risk (e.g., consumption of blood) or decrease risk (e.g.,  
818 refusing to eat meat from dead animals) [173], and mitigation efforts that persist  
819 between outbreaks. As these factors can be confounded, an in-depth understanding of  
820 RVFV epidemiology is needed to design investigations so that resources for operational  
821 research can be maximized.

822 **Gap 2: The unpredictability of livestock herd immunity** Current prevention  
823 and readiness efforts for RVFV outbreaks rely mostly on early warning prediction and a

824 rapid livestock vaccination response, both of which occur with variable reliability.  
825 Recovery from infection and vaccination with live-attenuated vaccines are thought to  
826 result in lifelong neutralizing antibodies in livestock [174] and indeed, if enough livestock  
827 could be vaccinated for RVFV, then human spillover would be unlikely [175]. However,  
828 livestock have a rapid turnover rate within and between herds as animals are  
829 slaughtered and sold, or arrive naïve into the herd from new births or purchases.  
830 Additionally, livestock in RVFV endemic countries often live in close proximity to wild  
831 ruminant species that also acquire many naïve animals each breeding season. The  
832 logistics and current intermittent nature of domestic livestock vaccination campaigns, in  
833 the face of unknown baseline herd immunity levels, makes full reliance on reactive  
834 livestock vaccination a risky approach to RVFV public health control.

835         Most livestock animal studies have focused on cattle, sheep, and goat  
836 seroprevalence. Although some surveys have used power analysis to determine how  
837 many animals to sample from each species, many surveys have still opted for  
838 convenience sampling, focusing either on sheep and goats, which are easier to handle,  
839 or on just cattle alone. The interpretation of such livestock prevalence surveys should  
840 be viewed with caution. Animal age is also likely to influence the results-- cattle and  
841 dairy animals tend to live longer than sheep or goats, so it can appear that their  
842 cumulative burden of exposure is higher. However, evidence of infection among  
843 younger animals does provide evidence for recent RVFV transmission activity, and  
844 increased seroprevalence between years can indicate an unrecognized outbreak. When  
845 multiple species are surveyed, rates should be calculated based on animal-years at risk  
846 and better attempts should be made to age animals based on their dentition. Factors

847 that confound RVFV exposure risk should be captured, such as the wealth and  
848 knowledge of the farmer [114], area livestock density, and location-specific climate  
849 factors. We suggest factors such as nearby temporary and permanent water bodies,  
850 land use, mobility at peak mosquito biting times, housing conditions, and rearing  
851 strategy be combined with climate data to better discern spatial and temporal high-risk  
852 periods for livestock. This will be important in defining optimal locations for human  
853 vaccination trials.

854 As the previous systematic review by Clark, et al. [68] has highlighted, and as we  
855 found in our review, there are few studies that assess both human and animals from the  
856 same site at the same time. The high-risk periods for livestock and humans may not  
857 necessarily overlap, as livestock infections are undoubtedly driven by rainfall and  
858 mosquito blooms, but human outbreaks can also expand with increased slaughtering of  
859 sick animals and the increased presence of secondary mosquito vectors.

860 It is understood that livestock viral amplification is an important predecessor of  
861 human outbreaks. The greater number of acute animal events (N=273), compared to  
862 human events (N=132) identified in this review could be due to our increasing ability to  
863 detect smaller animal outbreaks or could represent our inability to reliably detect acute  
864 human cases associated with smaller animal outbreaks [176, 177]. After animal  
865 outbreaks are established, we recommend broad-based human outbreak investigations  
866 that include all community members, not just the high-risk individuals, i.e., all individuals  
867 who may have had contact with animal products from the affected herd, as well as  
868 those who do not own livestock but reside in areas within vector flight range.

869           **Gap 3: Differences in seasonality across endemic/enzootic locations.** As  
870 climate change modifies seasonal weather patterns, differences in outbreak incidence  
871 are becoming more prominent among at-risk locations, but these changes may make  
872 epidemics harder to predict. Eighty-nine (31%) of our included studies specifically  
873 mention flooding at the outbreak site. A defined “rainy season” and “dry season” in  
874 tropical locations can guide risk assessment, but it is not just rain that makes an  
875 outbreak more likely. Congregation of many susceptible hosts and large volume  
876 slaughtering of animals (for example, as part of religious or community festivals [148,  
877 178, 179]), an abundance of mosquito breeding containers (for example, in plastic  
878 trash) [180], large-scale animal movement [181], and low baseline herd immunity will  
879 increase the chance of RVFV outbreaks. Recent data-driven modeling efforts by  
880 Hardcastle and colleagues [59], incorporating environmental and human and animal  
881 census data at the district level, predict that outbreaks in southern and eastern Africa  
882 are most likely to occur in December through July, whereas risk in the Sahelian zone  
883 will be higher in September through November [182]. Even within countries, seasonal  
884 rainfall can vary widely. For example, in western Kenya, August typically has above  
885 average rainfall while the remainder of the country remains dry [183]. Real-time regional  
886 level weather information must be considered to obtain adaptive implementation of  
887 mitigation efforts.

888           Pastoralist herds tend to have higher RVFV exposure, and this is influenced by  
889 the types of ecozones where the herds circulate. Pastoralists follow water and pasture  
890 availability as they become available in a seasonal cycle, which may involve movement  
891 through high-risk zones. As animal protein demand increases, mostly in urban centers,

892 more livestock will be passing through areas that have previously experienced RVF  
893 cases, and in the presence of competent mosquito vectors. Recent infections are more  
894 common in nomadic herds compared to agro-pastoralist herds [184] and in herds with  
895 longer distance to travel to their night pens or to the nearest permanent water [83].  
896 Modeling of data from Senegal suggested that nomadic herd movements are sufficient  
897 to account for endemic circulation of RVFV, although the co-existence of *Aedes* vertical  
898 transmission cannot be ruled out [185].

899 In addition to climate, the variety of suitable hosts present in those areas will also  
900 vary from location to location. All potential wildlife reservoir species should be  
901 considered when comparing incidences between two geographically distinct areas  
902 because wild animals' behaviors and range is intimately tied to topography and  
903 resource availability. In Botswana, wildlife hunters' seroprevalence was 27% compared  
904 to a 3% community level exposure [35], showing that wildlife exposure may contribute  
905 directly to human burden independent of domestic livestock presence. This is further  
906 illustrated by human case exposure in Angola without documented livestock exposure  
907 [101]. As RVFV can adapt to new ecological niches and utilize a wide variety of  
908 mammals to amplify itself, including common white-tail deer [186, 187], we caution not  
909 to make the assumption that wild animals' role in RVFV transmission will be similar  
910 between locations. All suitable wild animals, particularly wild ungulates, should be  
911 included in calculations of regional herd immunity and their interface with humans  
912 should be considered as a likely risk factor.

913 **Gap 4: Data challenges related to bias based on limited study designs and**  
914 **inconsistent reporting.** A systematic review by Bron and colleagues [188] has

915 summarized the patchwork of data collected on RVFV epidemiology over the last  
916 century, and has highlighted the lack of standardized reporting as the major challenge in  
917 comparing data between locations. In our current systematic review, which focused  
918 solely on studies from the last two decades, we confirm that uneven reporting remains a  
919 significant problem. Improving study designs and sampling frameworks for RVFV is  
920 challenging, in part due to the lack of funding opportunities during interepidemic periods.  
921 In outbreak reports, uncertain levels of ascertainment bias and possible diagnostic  
922 misclassification mean that case finding and resulting case counts have unclear  
923 accuracy. 'Population at risk' numbers used in incidence and prevalence calculations  
924 are often chosen based on outdated census data without true understanding of who is  
925 at risk within a community. With many smaller, low-budget, short-term studies (rather  
926 than large collaborative long-term efforts) the focus turns to identifying enough cases for  
927 a meaningful statistical analysis, which means that some studies will test only high-risk  
928 individuals working with animals. This likely excludes vulnerable populations who have  
929 not yet been identified as being at high-risk.

930 Hospital-based surveys for hemorrhagic fever surveillance are an attractive tool  
931 because they do not require household field visits and blood samples are typically more  
932 available for testing [38, 40, 152-154, 189, 190]. Such sero-surveillance can be  
933 compared from year to year to gain retrospective insight on when transmission has  
934 occurred. However, as with most hospital-based studies, these efforts do not represent  
935 the population at large, so they likely underestimate true incidence and overestimate the  
936 percentage of cases with severe disease.



937           **Gap 5: Delineating human risk factors.** Limitations in our knowledge of  
938 detailed human risk factors undermines ability to use targeted strategies, such as  
939 human anti-RVFPV vaccination, for prevention. For vaccine development, the predefined  
940 geographic site(s) in which clinical trials will be conducted must contain individuals who:  
941 1) are likely to be at a high infection risk during the trial; 2) are likely to exhibit the  
942 primary endpoint upon infection; and 3) represent populations in which the vaccine will  
943 likely be distributed if found efficacious. Our meta-analysis of human risk factors across  
944 multiple 1999-2021 studies confirms the increased RVFPV infection risk associated with  
945 male gender, general livestock care, contact with animal abortion, butchering animals,  
946 and milking risks identified in previous reviews and meta-analysis [65, 191]. Not all of  
947 the studies in this systematic review were population-based, thus the variable reporting  
948 of associations having ‘statistical significance’ may be attributed to differences in study  
949 design, low sample size (with lack of statistical power), and/or choice of target  
950 populations.

951           In most places where RVFPV outbreaks occur, lack of health care infrastructure  
952 impedes detailed description of human disease signs and performance of laboratory  
953 studies (including assessment of viral load and immunologic responses to infection),  
954 which might be predictive of severe disease or death. It is possible that other health  
955 comorbidities, such as concurrent HIV or hepatitis, can influence the presentation of  
956 RVFPV disease, but these associations have not yet been widely studied. Further  
957 descriptions of the natural history of clinical and laboratory findings in human RVF are  
958 needed, and efforts should be made to fully assess the relative risks from direct (non-  
959 vector) animal exposures vs. mosquito vector-borne exposure. Frontline healthcare

960 workers need to recognize when testing for RVFV infection is appropriate, based on  
961 patients' significant risk factors, and they should communicate frequently with local  
962 veterinary colleagues to identify high-risk transmission periods.

963 Most risk factor analyses rely on participant recall, risking recall bias, and it has  
964 been difficult to discriminate the risk of living in the presence of susceptible livestock  
965 from risk due to direct participation in husbandry activities or from risk due to local  
966 mosquito exposure (including variably zoophilic and anthropophilic mosquito species).  
967 Aside from animal rearing activities, the association of human risk with consumption of  
968 infected animal products is concerning, as this is practiced by a majority of human  
969 populations and the true infectivity by consumption is still not well understood. For  
970 example, consumption of raw milk is a now well recognized as an RVFV exposure risk  
971 factor [65, 191], but no previous studies have isolated RVFV from milk during outbreaks.  
972 Ongoing studies in Kenya [192] are conducting risk assessments in urban areas to  
973 distinguish consumption risk factors versus risk from livestock rearing activities common  
974 to rural areas.

975 RVF has been perceived as a disease of poverty, but this is likely due to its  
976 greater incidence recognized in rural areas. It is not known whether RVFV has an urban  
977 transmission cycle, and so far, the risk of RVF related to socioeconomic status (aside  
978 from having a pastoralist lifestyle) is poorly defined. Choice of occupation is intimately  
979 connected to socioeconomic status and this systematic review confirmed that the  
980 highest-risk occupations are associated with livestock exposure. Even within  
981 occupational categories, differences in assigned tasks can carry differential risks [193].  
982 We combined common terminology for the same profession, for example,

983 slaughterhouse and abattoir workers for our analysis; however, more specific factors  
984 such as size of the slaughterhouse, species slaughtered, and available personal  
985 protective equipment (PPE) are likely strong confounding factors.

986 **Gap 6: Need for consistent naming of RVFV lineages and strains.** A possible  
987 explanation for variation in RVF attack rates and disease severity, noted between  
988 locations and among different hosts, could be differences in RVFV strain virulence.  
989 Laboratory studies suggest some strain-specific differences in mortality in experimental  
990 animals [194]. However, the variability observed during natural outbreaks is likely due to  
991 site-related diagnostic misclassification of RVFV infection with erratic ability to detect  
992 milder cases of disease and variable presentations due to patients' age and health  
993 status. Our systematic review aimed to capture strain- and lineage-specific effects;  
994 however, a meaningful analysis was obscured by inconsistent naming of lineages due  
995 to differences in the genetic sequences chosen to be studied and different approaches  
996 to sequence homology analysis. International harmonization of lineage identity and  
997 nomenclature will help to determine differential effects, if any, of individual RVFV  
998 lineages and strains. Formal delineation could be applied to study lineage and strain as  
999 a potential confounders in RVF outcome measures such as disease severity in larger-  
1000 scale multi-center vaccination trials. As with SARS-CoV2 variants, a naming scheme  
1001 that does not rely on location may help to alleviate some of the disincentive and stigma  
1002 for national governments to report acute cases and identify sequences of circulating  
1003 genomes to identify sources of local introduction.

1004 **Gap 7: Need for consistent RVFV testing frameworks.** As highlighted earlier,  
1005 identification of RVFV outbreaks and determination of the endemic state of a country

1006 require consideration of the efficacy of surveillance efforts in place. Well organized and  
1007 implemented surveillance systems provide the basis for understanding the epidemiology  
1008 of RVFV and provide an opportunity for warning and an opportunity to fill the gaps in  
1009 current knowledge.

1010 As RVFV diagnostics become more widely available, physicians in  
1011 hyperendemic regions will be able to consider co-infection with RVFV in their differential  
1012 diagnoses, especially for pregnant mothers who are at risk for abortion [170].  
1013 Additionally, if hospitals are aware of current RVFV circulation in livestock, they can go  
1014 on high-alert and intensify their screening of patients for RVF. However, the lack of  
1015 specific medical therapeutics may dissuade clinicians from testing for RVFV and favor  
1016 testing for more treatable conditions, notably malaria. As the recent experience with  
1017 Ebola virus in West Africa has taught, compassionate care must be the cornerstone of  
1018 outbreak response in order for the at-risk population to buy into control measures.  
1019 Public health messaging that fuels despair results in massive underreporting,  
1020 particularly if outbreaks become political [195].

1021 There are concerted efforts to create a pan-viral hemorrhagic fever diagnostic  
1022 assay. The Uganda Virus Research Institute (UVRI) in Entebbe has been implementing  
1023 laboratory-based surveillance for viral hemorrhagic fevers (VHF) in Uganda since 2010,  
1024 which includes testing for RVFV [196]. While this may help differentiate RVFV from  
1025 other concerning viruses, we caution about the grouping of RVFV with other  
1026 hemorrhagic fevers for surveillance purposes as RVF-related hemorrhage in humans is  
1027 the rarest clinical manifestation, and the risk factors for other forms of RVFV-related  
1028 disease are different.

1029           Development of robust RVFV surveillance systems is complex, because both  
1030 animals and humans display variably detectable disease outcomes when they become  
1031 infected. Currently, most RVFV surveillance systems are engaged only in response to  
1032 climate early warning systems and are focused on periods with high-risk for large scale  
1033 outbreaks. We found that recent re-structuring of the FAO Global Animal Disease  
1034 Information System (EMPRESi) has provided an open-source, easy to navigate platform  
1035 for tracking reports of RVFV cases in member countries. Since 2004, the system has  
1036 recorded 1,186 animal cases of RVFV, of which 1,175 were confirmed. This reporting  
1037 system relies on mandatory reporting of acute cases by national authorities, the OIE,  
1038 WHO, FAO field officers, and published reports such as those included in this review.  
1039 However, this database excludes longitudinal seroconversions, and therefore, excludes  
1040 evidence of sub-clinical transmission during interepidemic periods and so does not  
1041 capture the full extent of RVFV burden. Future modeling approaches using only these  
1042 data should consider this key missing piece in their assumptions. The lack of consistent  
1043 and systematic open-source data capture currently impedes the design of both animal  
1044 and human vaccine trials. Although RVFV is a reportable disease in many of the  
1045 affected countries, a system that relies on passive reporting is likely to miss areas of  
1046 new emergence when viral activity is below the threshold to detect excess numbers of  
1047 patients with the more obvious clinical signs of RVF. It should be noted that the  
1048 partnership of a strong national veterinary service with close ties to a fully equipped  
1049 national laboratory is crucial to any successful surveillance effort. If farmer-based  
1050 cellphone reporting is to be successful at identifying RVF cases, farmers need to be  
1051 sensitized to the greater goals of the system and incentivized to report. Overall, the

1052 ideal surveillance system for RVFV would utilize aspects of each of the discussed  
1053 surveillance types (Fig 10), focusing on sentinels and enhanced active case finding,  
1054 including during interepidemic periods, and take into account regional differences in  
1055 animal and human health systems. Since RVFV is a vector-transmitted disease, and a  
1056 large proportion of the world has the potential for RVFV emergence, the management of  
1057 RVFV surveillance efforts should be regionally collaborated and all RVFV-naive  
1058 countries with large numbers of livestock should take into account past lessons about  
1059 recent introductions into new geographic areas as they prepare prevention and  
1060 mitigation efforts for themselves [197-202].

1061       Post-epidemic performance analyses have found that the lead time given by  
1062 early warning systems may not be sufficiently long to prepare and vaccinate enough  
1063 livestock to contain an outbreak. Just as reliance on a passive surveillance system for  
1064 RVFV is likely to not be enough to detect outbreaks, sole reliance on a remotely sensed  
1065 early warning systems (EWS) should also be avoided. One major limitation of climatic  
1066 EWS is that they do not account for the effect of existing herd immunity, obtained either  
1067 through natural infection or prior livestock vaccination. Livestock seroprevalence as high  
1068 as 60% have been captured in high risk areas [203] and up to 38% in areas that are not  
1069 typically classified as high risk, such as Chad [204]. The lack of outbreak detection,  
1070 despite seemingly high-risk weather conditions, can be explained both by the effect of  
1071 herd immunity and limitations of existing surveillance systems. With this current level of  
1072 performance, at-risk countries should not rely solely on early warning systems and  
1073 instead use them as part of integrated decision support tools, similar to those developed  
1074 for the greater Horn of Africa [205]. As RVFV outbreaks have often had an insidious

1075 onset, we recommend active case finding in high-risk areas in response to any of the  
1076 previously mentioned early warning signals.

1077 **Gap 8: Evolving better approaches to diagnostics.** Because arboviral  
1078 infections such as RVF often result in self-limited febrile syndromes with non-specific  
1079 signs and symptoms, isolated cases of infection are frequently misdiagnosed as malaria  
1080 in sub-Saharan Africa. This highlights the critical need for affordable and accurate point-  
1081 of-care diagnostics for RVFV [206-209]. In the majority of recent transmission surveys,  
1082 anti-RVFV IgM serology was used alone to define recent infection, and more humans  
1083 than animals were found to be positive. As commercial IgM ELISA tests are now more  
1084 widely available for livestock, this gap likely represents a lack of available resources,  
1085 either financial or logistical, for testing livestock for recent infection. For suspect acute  
1086 cases, IgM allows a wider window of detection than discovery of circulating virus or viral  
1087 RNA [210].

1088 Among the 95 studies that reported human serology, the methods for human  
1089 anti-RVFV antibody detection exhibited significant variability, with most studies relying  
1090 on tertiary reference laboratories for final diagnosis. Future efforts should focus on  
1091 increasing the number and capacity of local laboratories so that the burden of shipping  
1092 time and costs can be alleviated. The Covid-19 pandemic response has led to  
1093 expansion of molecular diagnostic capacity in many regions. In the aftermath of the  
1094 pandemic, these important logistical and laboratory resources should be leveraged to  
1095 include other viral diseases such as RVF.

1096 Serology serves as the basic approach for investigating individual and  
1097 community level risk factors as it can monitor changes in prevalence over time. Both



1098 enzyme-linked immunosorbent assays (ELISA) and viral neutralization tests (VNT) have  
1099 advantages and disadvantages. Identifying IgG-positive livestock by ELISA has often  
1100 been the first step in recognizing new areas of emergence [81, 211]. However, follow up  
1101 VNT should be used to confirm positive ELISA results in new locations, especially if the  
1102 seroprevalence is low (less than 1-2%) when misclassification due to false-positive tests  
1103 is of concern. For future vaccination trials, if seroconversion is the primary measure of  
1104 local RVF occurrence in livestock, greater emphasis on the availability of diagnostic  
1105 techniques of differentiating infected from vaccinated animals (DIVA) will be needed.

1106 **Gap 9: The need for One Health approaches for RVFV detection and**  
1107 **control.** Expanding RVFV surveys to include human community populations at-large  
1108 will identify risk associated with socioeconomic standing, while simultaneously detecting  
1109 patients with incident infections but without presently known risk factors. To fully  
1110 understand the ecology of local transmission such broad-based human studies need to  
1111 be conducted concurrently with robust animal surveys. Recent reviews and policy  
1112 papers in the human and animal health RVFV literature call for a greater emphasis on a  
1113 One Health management approach, both in research and control efforts [128, 212, 213].  
1114 For vaccination strategies, application of a One Health approach would focus on the  
1115 combined use of veterinary and human vaccinations. A better understanding of viral  
1116 transmission to all species during interepidemic periods, with an improvement of  
1117 diagnostic sampling frameworks, are within reach in the next decade. Reaching an  
1118 understanding of the herd immunity threshold for outbreak initiation, the variability in  
1119 case fatality risks, the contributions of vectors to both asymptomatic and symptomatic

1120 human and animal infections, and the most influential transmission pathways will take a  
1121 collaborative effort among multiple disciplines and public health sectors.

1122 **Summary.** The gaps presented here are based on a collated estimates of recent  
1123 RVFV transmission. The available case counts and serosurveys in this systematic  
1124 review contribute to a body of evidence that can guide the way forward to clinical testing  
1125 of novel preventive and curative interventions.

1126 The identified gaps will all affect development of human vaccines for RVF, acting  
1127 as potential impediments to planning and preparing clinical field trials. Trial feasibility  
1128 will depend on understanding incidence with sufficient granularity and identification of  
1129 suitable target populations. Site selection faces challenges in forecasting-- timing,  
1130 duration and location of outbreaks, and study population selection will depend on  
1131 existing seroprevalence and the duration of protection after prior natural exposure and  
1132 infection. Definition of clinical endpoints will depend on good characterization of clinical  
1133 presentations, and availability of diagnostic tests for differentiating non-specific febrile  
1134 syndromes.

1135 RVFV continues to transmit across Africa and nearby Indian Ocean islands at a  
1136 high rate, but at an irregular frequency. As previously noted, because of its typical  
1137 mosquito-borne re-emergent transmission, RVFV outbreaks often follow periods of  
1138 excess rainfall and local flooding, particularly in semi-arid regions. During the 1999-  
1139 2021 period studied in this review, human outbreaks of RVF occurred at an average  
1140 rate of 5-6 events per year across the region. The range of transmission has expanded,  
1141 with human cases documented for the first time in Saudi Arabia, Yemen, Comoros,  
1142 Mayotte, Burundi, Niger, and Mali, and with re-emergence in Uganda after multiple

1143 decades of no activity. Reported human RVF events were most common in Mauritania,  
1144 Kenya, Sudan, Madagascar, and South Africa, and each of these countries experienced  
1145 multiple epidemics since 1999. In districts or counties where human cases were  
1146 reported, the median attack rate was 2.5 per 100,000 (range 0.1 to 91), and median  
1147 case fatality was 14.3% of severe cases, highlighting the significant population health  
1148 burden of RVF.

1149 Experience with veterinary vaccines indicates that pre-event vaccination can  
1150 mitigate the spread of RVFV infection. Now that human vaccines are under  
1151 development, their clinical testing and implementation should be guided by particular  
1152 focus on the high-risk subgroups (based on location and exposures) identified in this  
1153 review. Effective vaccine trials will depend on achieving accurate outbreak predictions  
1154 combined with efficient animal and human case surveillance systems.

1155 The feasibility of such trials can be assessed using the present summary of  
1156 recent epidemiology, while approaches to trial design will be strengthened by  
1157 simultaneously addressing the gaps we have discussed here. Recommendations for  
1158 vaccine trial study design will be addressed in greater detail in a subsequent paper by  
1159 the CEPI RVF study group.

1160

## 1161 **Acknowledgments**

1162 The authors would like to acknowledge the very helpful guidance provided by members  
1163 of the CEPI literature review advisory group: Dr. Brian Bird, Dr. Baptiste Dungu, Roice  
1164 Fulton, Dr. Jeroen Kortekaas, Dr. Paul Oloo, Dr. Janusz Paweska, Dr. Melinda Rostal,  
1165 and Dr. George Warimwe.

## 1166 **Figure legends**

1167 **Fig 1. PRISMA systematic review flow diagram of data collection and evaluation**  
1168 Online searches for publications and data registers (left side flow) were supplemented  
1169 by governmental outbreak reports, non-indexed citations found in local archives, and  
1170 citations found within the reference lists of the papers that were reviewed (right side  
1171 flow).

1172  
1173 **Fig 2. Regional map of countries exposed to RVFV infection based on findings of**  
1174 **studies included in the systematic review.** Countries were categorized as to whether  
1175 there was evidence of human, animal, or arthropod RVFV infection during the 1999-  
1176 2021 era. Base map is from Database of Global Administrative Areas (GADM) (version  
1177 3.4, (April 2018, [www.gadm.org/data.html](http://www.gadm.org/data.html))

1178  
1179 **Fig 3. Sub-national administrative regions experiencing acute human cases of**  
1180 **RVF during the years 1999-2021** Locations are shaded according to whether they  
1181 experienced outbreaks before or after 2011, or if they had outbreaks during both  
1182 periods of time. Base map is from Database of Global Administrative Areas (GADM)  
1183 (version 3.4, (April 2018, [www.gadm.org/data.html](http://www.gadm.org/data.html))

1184  
1185 **Fig 4. Sub-national administrative regions experiencing acute animal cases of**  
1186 **RVF during the years 1999-2021** Locations are shaded according to whether they  
1187 experienced outbreaks before or after 2011, or during both periods of time. Base map is  
1188 from Database of Global Administrative Areas (GADM) (version 3.4, (April 2018,  
1189 [www.gadm.org/data.html](http://www.gadm.org/data.html))

1190  
1191 **Fig 5. Acute human RVF events per year during 1999-2021, by geographic regions**  
1192 **across Africa, the Indian Ocean, and the Arabian Peninsula**

1193  
1194 **Fig 6. Acute animal RVF events per year during 1999-2021, by geographic regions**  
1195 **across Africa, the Indian Ocean, and the Arabian Peninsula**

1196  
1197 **Fig 7 Meta-analysis of the impact of human gender on odds of RVFV exposure in**  
1198 **at-risk populations**

1199  
1200 **Fig 8 Meta-analysis of the impact of animal exposure on odds of RVFV exposure**  
1201 **in at-risk populations.**

1202  
1203 **Fig 9 Meta-analysis of the impact of handling RVF-related animal abortions on**  
1204 **odds of human RVFV exposure in at-risk populations**

1205  
1206 **Fig 10 Progressive scale of surveillance that can used to indicate an impending**  
1207 **RVFV disease outbreak.** Republished with permission of The National Academies  
1208 Press, from Under the Weather: Climate, Ecosystems, and Infectious Disease (2001),  
1209 Chapter 7: Towards the Development of Disease Early Warning Systems. P. 87;

1210 permission conveyed through Copyright Clearance Center, Inc. under license ID  
1211 #1142222

1212

## 1213 **References**

1214 1. Gubler DJ. The global emergence/resurgence of arboviral diseases as public health  
1215 problems. Arch Med Res. 2002;33(4):330-342. Epub 2002/09/18. doi: 10.1016/s0188-  
1216 4409(02)00378-8.

1217

1218 2. CDC. Rift Valley Fever. Viral Hemorrhagic Fevers: Fact Sheets. 2002:1-3.

1219

1220 3. Isaäcson M. Viral hemorrhagic fever hazards for travelers in Africa. Clin Infect Dis.  
1221 2001;33(10):1707-1712. Epub 2001/10/12. doi: 10.1086/322620.

1222

1223 4. WHO. Rift Valley Fever. WHO Fact Sheet No 207. 2018:1-5. Epub 19 Feb 2018.

1224

1225 5. Munyua P, Murithi RM, Wainwright S, Githinji J, Hightower A, Mutonga D, et al. Rift  
1226 Valley fever outbreak in livestock in Kenya, 2006-2007. Am J Trop Med Hyg. 2010;83(2  
1227 Suppl):58-64. Epub 2010/08/13. doi: 10.4269/ajtmh.2010.09-0292.

1228

1229 6. CDC. Outbreak of Rift Valley fever--Yemen, August-October 2000. MMWR.  
1230 2000;49(47):1065-1066.

1231

1232 7. Woods CW, Karpati AM, Grein T, McCarthy N, Gaturuku P, Muchiri E, et al. An  
1233 outbreak of Rift Valley fever in Northeastern Kenya, 1997-98. Emerg Infect Dis.  
1234 2002;8(2):138-144. Epub 2002/03/19. doi: 10.3201/eid0802.010023.

1235

1236 8. Daubney R, Hudson JR, Garnham PC. Enzootic hepatitis or Rift Valley fever: an  
1237 undescribed virus disease of sheep, cattle and man from East Africa. Journal of  
1238 Pathology and Bacteriology. 1931;34:545-579.

1239

1240 9. CDC. Update: Outbreak of Rift Valley Fever - Saudi Arabia, August-November 2000.  
1241 MMWR. 2000;49(43):982-985.

1242

1243 10. Golnar AJ, Turell MJ, LaBeaud AD, Kading RC, Hamer GL. Predicting the mosquito  
1244 species and vertebrate species involved in the theoretical transmission of Rift Valley  
1245 fever virus in the United States. PLoS Negl Trop Dis. 2014;8(9):e3163. doi:  
1246 10.1371/journal.pntd.0003163.

1247

- 1248 11. Iranpour M, Turell MJ, Lindsay LR. Potential for Canadian mosquitoes to transmit  
1249 Rift Valley fever virus. J Am Mosq Control Assoc. 2011;27(4):363-369. Epub  
1250 2012/02/15. doi: 10.2987/11-6169.1.
- 1251
- 1252 12. Turell MJ, Dohm DJ, Geden CJ, Hogsette JA, Linthicum KJ. Potential for stable flies  
1253 and house flies (Diptera: Muscidae) to transmit Rift Valley fever virus. J Am Mosq  
1254 Control Assoc. 2010;26(4):445-448. Epub 2011/02/05. doi: 10.2987/10-6070.1.
- 1255
- 1256 13. Turell MJ, Wilson WC, Bennett KE. Potential for North American mosquitoes  
1257 (Diptera: Culicidae) to transmit Rift Valley fever virus. J Med Entomol. 2010;47(5):884-  
1258 889. Epub 2010/10/14. doi: 10.1603/me10007.
- 1259
- 1260 14. Gargan TP, 2nd, Clark GG, Dohm DJ, Turell MJ, Bailey CL. Vector potential of  
1261 selected North American mosquito species for Rift Valley fever virus. Am J Trop Med  
1262 Hyg. 1988;38(2):440-446. doi: 10.4269/ajtmh.1988.38.440.
- 1263
- 1264 15. Turell MJ, Bailey CL, Beaman JR. Vector competence of a Houston, Texas strain of  
1265 *Aedes albopictus* for Rift Valley fever virus. J Am Mosq Control Assoc. 1988;4(1):94-96.
- 1266
- 1267 16. Chengula AA, Mdegela RH, Kasanga CJ. Socio-economic impact of Rift Valley  
1268 fever to pastoralists and agro pastoralists in Arusha, Manyara and Morogoro regions in  
1269 Tanzania. Springerplus. 2013;2:549. Epub 2013/11/21. doi: 10.1186/2193-1801-2-549.
- 1270
- 1271 17. Holleman C. The socio-economic implications of the livestock ban in Somaliland.  
1272 2002.
- 1273
- 1274 18. Muga GO, Onyango-Ouma W, Sang R, Affognon H. Sociocultural and economic  
1275 dimensions of Rift Valley fever. Am J Trop Med Hyg. 2015;92(4):730-738. Epub  
1276 2015/02/18. doi: 10.4269/ajtmh.14-0363.
- 1277
- 1278 19. Rich KM, Wanyoike F. An assessment of the regional and national socio-economic  
1279 impacts of the 2007 Rift Valley fever outbreak in Kenya. Am J Trop Med Hyg. 2010;83(2  
1280 Suppl):52-57. doi: 10.4269/ajtmh.2010.09-0291.
- 1281
- 1282 20. Riou O, Phillipe B, Jouan A, Coulibaly I, Mondo M, Digoutte JP. Les formes  
1283 neurologiques et neurosensorielles de la fièvre de Valley du Rift en Mauritanie. Bulletin  
1284 de la Societe de Phologie Exotiques. 1989;82:605-610.
- 1285

- 1286 21. Kahlon SS, Peters CJ, Leduc J, Muchiri EM, Muiruri S, Njenga MK, et al. Severe  
1287 Rift Valley fever may present with a characteristic clinical syndrome. *Am J Trop Med*  
1288 *Hyg.* 2010;82(3):371-375. doi: 10.4269/ajtmh.2010.09-0669.
- 1289  
1290 22. Kim Y, Metras R, Dommergues L, Youssouffi C, Combo S, Le Godais G, et al. The  
1291 role of livestock movements in the spread of Rift Valley fever virus in animals and  
1292 humans in Mayotte, 2018-19. *PLoS Negl Trop Dis.* 2021;15(3):e0009202. doi:  
1293 10.1371/journal.pntd.0009202.
- 1294  
1295 23. OIE. Rift Valley Fever (RVF): OIE; 2021. Available from:  
1296 <https://www.oie.int/en/animal-health-in-the-world/animal-diseases/rift-valley-fever/>.
- 1297  
1298 24. Davies FG, Linthicum KJ, James AD. Rainfall and epizootic Rift Valley Fever. *Bull*  
1299 *World Health Organ.* 1985;63:941-943.
- 1300  
1301 25. Linthicum KJ, Anyamba A, Tucker CJ, Kelley PW, Myers MF, Peters CJ. Climate  
1302 and satellite indicators to forecast Rift Valley Fever epidemics in Kenya. *Science.*  
1303 1999;285:397-400.
- 1304  
1305 26. Linthicum KJ, Bailey CL, Davies FG, Tucker CJ. Detection of Rift Valley fever viral  
1306 activity in Kenya by satellite remote sensing imagery. *Science.* 1987;235(4796):1656-  
1307 1659. Epub 1987/03/27.
- 1308  
1309 27. Linthicum KJ, Bailey CL, Tucker CJ, Mitchell KD, Logan TM, Davies FG, et al.  
1310 Application of polar-orbiting, meteorological satellite data to detect flooding of Rift Valley  
1311 fever virus vector mosquito habitats in Kenya. *Med Vet Entomol.* 1990;4(4):433-438.  
1312 Epub 1990/10/01.
- 1313  
1314 28. Anyamba A, Chretien JP, Formenty PB, Small J, Tucker CJ, Malone JL, et al. Rift  
1315 Valley fever potential, Arabian Peninsula. *Emerg Infect Dis.* 2006;12(3):518-520. Epub  
1316 2006/05/23. doi: 10.3201/eid1203.050973.
- 1317  
1318 29. Anyamba A, Chretien JP, Small J, Tucker CJ, Formenty PB, Richardson JH, et al.  
1319 Prediction of a Rift Valley fever outbreak. *Proc Natl Acad Sci U S A.* 2009;106(3):955-  
1320 959. doi: 10.1073/pnas.0806490106.
- 1321  
1322 30. Anyamba A, Chretien JP, Small J, Tucker CJ, Linthicum KJ. Developing global  
1323 climate anomalies suggest potential disease risks for 2006-2007. *Int J Health Geogr.*  
1324 2006;5:60. Epub 2006/12/30. doi: 10.1186/1476-072x-5-60.



- 1325  
1326 31. Anyamba A, Linthicum KJ, Small J, Britch SC, Pak E, de La Rocque S, et al.  
1327 Prediction, assessment of the Rift Valley fever activity in East and southern Africa 2006-  
1328 2008 and possible vector control strategies. *Am J Trop Med Hyg.* 2010;83(2 Suppl):43-  
1329 51. doi: 10.4269/ajtmh.2010.09-0289.
- 1330  
1331 32. Anyamba A, Linthicum KJ, Tucker CJ. Climate-disease connections: Rift Valley  
1332 fever in Kenya. *Cad Saude Publica.* 2001;17 Suppl:133-140. Epub 2001/06/27. doi:  
1333 10.1590/s0102-311x2001000700022.
- 1334  
1335 33. Ahmed A, Makame J, Robert F, Julius K, Mecky M. Sero-prevalence and spatial  
1336 distribution of Rift Valley fever infection among agro-pastoral and pastoral communities  
1337 during interepidemic period in the Serengeti ecosystem, northern Tanzania. *BMC Infect*  
1338 *Dis.* 2018;18(1):276. Epub 2018/06/15. doi: 10.1186/s12879-018-3183-9.
- 1339  
1340 34. Tigoi C, Sang R, Chepkorir E, Orindi B, Arum SO, Mulwa F, et al. High risk for  
1341 human exposure to Rift Valley fever virus in communities living along livestock  
1342 movement routes: A cross-sectional survey in Kenya. *PLoS Negl Trop Dis.*  
1343 2020;14(2):e0007979. Epub 2020/02/23. doi: 10.1371/journal.pntd.0007979.
- 1344  
1345 35. Sanderson CE, Jori F, Moolla N, Paweska JT, Oumer N, Alexander KA. Silent  
1346 circulation of Rift Valley fever in humans, Botswana, 2013-2014. *Emerg Infect Dis.*  
1347 2020;26(10):2453-2456. Epub 2020/09/19. doi: 10.3201/eid2610.191837.
- 1348  
1349 36. Schoepp RJ, Rossi CA, Khan SH, Goba A, Fair JN. Undiagnosed acute viral febrile  
1350 illnesses, Sierra Leone. *Emerging Infectious Diseases.* 2014;20(7):1176-1182. doi:  
1351 10.3201/eid2007.131265.
- 1352  
1353 37. Bosworth A, Ghabbari T, Dowall S, Varghese A, Fares W, Hewson R, et al.  
1354 Serologic evidence of exposure to Rift Valley fever virus detected in Tunisia. *New*  
1355 *Microbes New Infect.* 2016;9:1-7. doi: 10.1016/j.nmni.2015.10.010.
- 1356  
1357 38. Dellagi K, Salez N, Maquart M, Larrieu S, Yssouf A, Silai R, et al. Serological  
1358 evidence of contrasted exposure to arboviral infections between islands of the Union of  
1359 Comoros (Indian Ocean). *Plos Neglected Tropical Diseases.* 2016;10(12). doi:  
1360 10.1371/journal.pntd.0004840.
- 1361  
1362 39. Durand JP, Bouloy M, Richecoeur L, Peyrefitte CN, Tolou H. Rift Valley fever virus  
1363 infection among French troops in Chad. *Emerg Infect Dis.* 2003;9(6):751-752. Epub  
1364 2003/06/05. doi: 10.3201/eid0906.020647.

- 1365  
1366 40. Guillebaud J, Bernardson B, Randriambolamanantsoa TH, Randrianasolo L,  
1367 Randriamampionona JL, Marino CA, et al. Study on causes of fever in primary  
1368 healthcare center uncovers pathogens of public health concern in Madagascar. PLoS  
1369 Negl Trop Dis. 2018;12(7):e0006642. Epub 2018/07/17. doi:  
1370 10.1371/journal.pntd.0006642.
- 1371  
1372 41. Gudo ES, Pinto G, Weyer J, le Roux C, Mandlaze A, José AF, et al. Serological  
1373 evidence of rift valley fever virus among acute febrile patients in Southern Mozambique  
1374 during and after the 2013 heavy rainfall and flooding: implication for the management of  
1375 febrile illness. Virol J. 2016;13:96. Epub 2016/06/10. doi: 10.1186/s12985-016-0542-2.
- 1376  
1377 42. Sow A, Faye O, Faye O, Diallo D, Sadio BD, Weaver SC, et al. Rift Valley fever in  
1378 Kedougou, southeastern Senegal, 2012. Emerg Infect Dis. 2014;20(3):504-506. Epub  
1379 2014/02/26. doi: 10.3201/eid2003.131174.
- 1380  
1381 43. Sumaye RD, Abatih EN, Thiry E, Amuri M, Berkvens D, Geubbels E. Inter-epidemic  
1382 acquisition of Rift Valley fever virus in humans in Tanzania. PLoS Negl Trop Dis.  
1383 2015;9(2):e0003536. Epub 2015/02/28. doi: 10.1371/journal.pntd.0003536.
- 1384  
1385 44. Liu J, Sun Y, Shi W, Tan S, Pan Y, Cui S, et al. The first imported case of Rift  
1386 Valley fever in China reveals a genetic reassortment of different viral lineages. Emerg  
1387 Microbes Infect. 2017;6(1):e4. Epub 2017/01/18. doi: 10.1038/emi.2016.136.
- 1388  
1389 45. Oltmann A, Kämper S, Staeck O, Schmidt-Chanasit J, Günther S, Berg T, et al.  
1390 Fatal outcome of hepatitis A virus (HAV) infection in a traveler with incomplete HAV  
1391 vaccination and evidence of Rift Valley fever virus infection. J Clin Microbiol.  
1392 2008;46(11):3850-3852. Epub 2008/09/05. doi: 10.1128/jcm.01102-08.
- 1393  
1394 46. Evans A, Gakuya F, Paweska JT, Rostal M, Akoolo L, Van Vuren PJ, et al.  
1395 Prevalence of antibodies against Rift Valley fever virus in Kenyan wildlife. Epidemiology  
1396 and Infection. 2008;136(9):1261-1269. doi: 10.1017/S0950268807009806.
- 1397  
1398 47. LaBeaud AD, Cross PC, Getz WM, Glinka A, King CH. Rift Valley fever virus  
1399 infection in African Buffalo (*Syncerus caffer*) herds in rural South Africa: Evidence of  
1400 interepidemic transmission. American Journal of Tropical Medicine and Hygiene.  
1401 2011;84(4):641-646. doi: 10.4269/ajtmh.2011.10-0187.
- 1402

- 1403 48. Olive MM, Goodman SM, Reynes JM. The role of wild mammals in the  
1404 maintenance of Rift Valley fever virus. *J Wildl Dis.* 2012;48(2):241-266. doi:  
1405 10.7589/0090-3558-48.2.241.
- 1406  
1407 49. Rostal MK, Evans AL, Sang R, Gikundi S, Wakhule L, Munyua P, et al.  
1408 Identification of potential vectors of and detection of antibodies against Rift Valley fever  
1409 virus in livestock during interepizootic periods. *American Journal of Veterinary*  
1410 *Research.* 2010;71(5):522-526. doi: 10.2460/ajvr.71.5.522.
- 1411  
1412 50. Pittman PR, Liu CT, Cannon TL, Makuch RS, Mangiafico JA, Gibbs PH, et al.  
1413 Immunogenicity of an inactivated Rift Valley fever vaccine in humans: a 12-year  
1414 experience. *Vaccine.* 1999;18(1-2):181-189. Epub 1999/09/29. doi: 10.1016/s0264-  
1415 410x(99)00218-2.
- 1416  
1417 51. Page MJ, McKenzie JE, Bossuyt PM, Boutron I, Hoffmann TC, Mulrow CD, et al.  
1418 The PRISMA 2020 statement: an updated guideline for reporting systematic reviews.  
1419 *Bmj.* 2021;372:n71. doi: 10.1136/bmj.n71.
- 1420  
1421 52. García-Bocanegra I, Paniagua J, Cano-Terriza D, Arenas-Montes A, Fernández-  
1422 Morente M, Napp S. Absence of Rift Valley fever virus in domestic and wild ruminants  
1423 from Spain. *Vet Rec.* 2016;179(2):48. Epub 2016/05/11. doi: 10.1136/vr.103696.
- 1424  
1425 53. Mentaberre G, Gutierrez C, Rodriguez NF, Joseph S, Gonzalez-Barrio D, Cabezon  
1426 O, et al. A transversal study on antibodies against selected pathogens in dromedary  
1427 camels in the Canary Islands, Spain. *Veterinary Microbiology.* 2013;167(3-4):468-473.  
1428 doi: 10.1016/j.vetmic.2013.07.029.
- 1429  
1430 54. Bazanow BA, Stygar D, Romuk E, Skrzep-Poloczek B, Pacon J, Gadzala L, et al.  
1431 Preliminary serological investigation of Rift Valley fever in Poland. *Journal of Vector*  
1432 *Borne Diseases.* 2018;55(4):324-326. doi: 10.4103/0972-9062.256570.
- 1433  
1434 55. Kim HJ, Park JY, Jeoung HY, Yeh JY, Cho YS, Choi JS, et al. Serological  
1435 surveillance studies confirm the Rift Valley fever virus free status in South Korea. *Trop*  
1436 *Anim Health Prod.* 2015;47(7):1427-1430. doi: 10.1007/s11250-015-0858-8.
- 1437  
1438 56. Batieha A, Saliba EK, Graham R, Mohareb E, Hijazi Y, Wijeyaratne P.  
1439 Seroprevalence of West Nile, Rift Valley, and sandfly arboviruses in Hashimiah, Jordan.  
1440 *Emerg Infect Dis.* 2000;6(4):358-362. Epub 2000/07/25. doi: 10.3201/eid0604.000405.
- 1441

- 1442 57. Freeman MC, Garn JV, Sclar GD, Boisson S, Medlicott K, Alexander KT, et al. The  
1443 impact of sanitation on infectious disease and nutritional status: A systematic review  
1444 and meta-analysis. *Int J Hyg Environ Health*. 2017;220(6):928-949. doi:  
1445 10.1016/j.ijheh.2017.05.007.
- 1446  
1447 58. Puzzolo E, Pope D, Stanistreet D, Rehfuss EA, Bruce NG. Clean fuels for  
1448 resource-poor settings: A systematic review of barriers and enablers to adoption and  
1449 sustained use. *Environ Res*. 2016;146:218-234. doi: 10.1016/j.envres.2016.01.002.
- 1450  
1451 59. Hardcastle AN, Osborne JCP, Ramshaw RE, Hulland EN, Morgan JD, Miller-Petrie  
1452 MK, et al. Informing Rift Valley fever preparedness by mapping seasonally varying  
1453 environmental suitability. *Int J Infect Dis*. 2020;99:362-372. Epub 2020/08/02. doi:  
1454 10.1016/j.ijid.2020.07.043.
- 1455  
1456 60. Redding DW, Tiedt S, Lo Iacono G, Bett B, Jones KE. Spatial, seasonal and  
1457 climatic predictive models of Rift Valley fever disease across Africa. *Philos Trans R Soc  
1458 Lond B Biol Sci*. 2017;372(1725). Epub 2017/06/07. doi: 10.1098/rstb.2016.0165.
- 1459  
1460 61. Williams R, Malherbe J, Weepener H, Majiwa P, Swanepoel R. Anomalous high  
1461 rainfall and soil saturation as combined risk indicator of Rift Valley fever outbreaks,  
1462 South Africa, 2008-2011. *Emerg Infect Dis*. 2016;22(12):2054-2062. Epub 2016/07/13.  
1463 doi: 10.3201/eid2212.151352.
- 1464  
1465 62. Hightower A, Kinkade C, Nguku PM, Anyangu A, Mutonga D, Omolo J, et al.  
1466 Relationship of climate, geography, and geology to the incidence of Rift Valley fever in  
1467 Kenya during the 2006-2007 outbreak. *American Journal of Tropical Medicine and  
1468 Hygiene*. 2012;86(2):373-380. doi: 10.4269/ajtmh.2012.11-0450.
- 1469  
1470 63. Verster AM, Liang JE, Rostal MK, Kemp A, Brand RF, Anyamba A, et al. Selected  
1471 wetland soil properties correlate to Rift Valley fever livestock mortalities reported in  
1472 2009-10 in central South Africa. *PLoS One*. 2020;15(5):e0232481. Epub 2020/05/19.  
1473 doi: 10.1371/journal.pone.0232481.
- 1474  
1475 64. Sindato C, Pfeiffer DU, Karimuribo ED, Mboera LE, Rweyemamu MM, Paweska JT.  
1476 A spatial analysis of Rift Valley fever virus seropositivity in domestic ruminants in  
1477 Tanzania. *PLoS One*. 2015;10(7):e0131873. Epub 2015/07/15. doi:  
1478 10.1371/journal.pone.0131873.
- 1479

- 1480 65. Nicholas DE, Jacobsen KH, Waters NM. Risk factors associated with human Rift  
1481 Valley fever infection: systematic review and meta-analysis. *Trop Med Int Health*.  
1482 2014;19(12):1420-1429. doi: 10.1111/tmi.12385.
- 1483  
1484 66. Higgins JP, Thompson SG. Quantifying heterogeneity in a meta-analysis. *Stat Med*.  
1485 2002;21(11):1539-1558. Epub 2002/07/12. doi: 10.1002/sim.1186.
- 1486  
1487 67. Deeks JJ, Altman DG, Bradburn MJ. Statistical methods for examining  
1488 heterogeneity and combining results from several studies in meta-analysis. In: Egger M,  
1489 Smith GD, Altman DG, editors. *Systematic Reviews in Health Care: Meta-analysis in*  
1490 *Context*. London: BMJ Books; 2001. p. 285-312.
- 1491  
1492 68. Clark MHA, Warimwe GM, Di Nardo A, Lyons NA, Gubbins S. Systematic literature  
1493 review of Rift Valley fever virus seroprevalence in livestock, wildlife and humans in  
1494 Africa from 1968 to 2016. *Plos Neglected Tropical Diseases*. 2018;12(7). doi:  
1495 10.1371/journal.pntd.0006627.
- 1496  
1497 69. LaBeaud AD, Muchiri EM, Ndzovu M, Mwanje MT, Muiruri S, Peters CJ, et al.  
1498 Interepidemic Rift Valley fever virus seropositivity, northeastern Kenya. *Emerg Infect*  
1499 *Dis*. 2008;14(8):1240-1246. doi: 10.3201/eid1408.080082.
- 1500  
1501 70. McElroy AK, Albariño CG, Nichol ST. Development of a RVFV ELISA that can  
1502 distinguish infected from vaccinated animals. *Virol J*. 2009;6:125. Epub 2009/08/15. doi:  
1503 10.1186/1743-422x-6-125.
- 1504  
1505 71. Paweska JT, Burt FJ, Swanepoel R. Validation of IgG-sandwich and IgM-capture  
1506 ELISA for the detection of antibody to Rift Valley fever virus in humans. *J Virol Methods*.  
1507 2005;124(1-2):173-181. Epub 2005/01/25. doi: 10.1016/j.jviromet.2004.11.020.
- 1508  
1509 72. Paweska JT, Jansen van Vuren P, Swanepoel R. Validation of an indirect ELISA  
1510 based on a recombinant nucleocapsid protein of Rift Valley fever virus for the detection  
1511 of IgG antibody in humans. *J Virol Methods*. 2007;146(1-2):119-124. Epub 2007/07/25.  
1512 doi: 10.1016/j.jviromet.2007.06.006.
- 1513  
1514 73. Jansen van Vuren P, Paweska JT. Laboratory safe detection of nucleocapsid  
1515 protein of Rift Valley fever virus in human and animal specimens by a sandwich ELISA.  
1516 *J Virol Methods*. 2009;157(1):15-24. Epub 2009/01/07. doi:  
1517 10.1016/j.jviromet.2008.12.003.
- 1518

- 1519 74. Wichgers Schreur PJ, Paweska JT, Kant J, Kortekaas J. A novel highly sensitive,  
1520 rapid and safe Rift Valley fever virus neutralization test. *J Virol Methods*. 2017;248:26-  
1521 30. doi: 10.1016/j.jviromet.2017.06.001.
- 1522
- 1523 75. Sobarzo A, Paweska JT, Herrmann S, Amir T, Marks RS, Lobel L. Optical fiber  
1524 immunosensor for the detection of IgG antibody to Rift Valley fever virus in humans.  
1525 *Journal of Virological Methods*. 2007;146(1-2):327-334. doi:  
1526 10.1016/j.jviromet.2007.07.017.
- 1527
- 1528 76. van der Wal FJ, Achterberg RP, de Boer SM, Boshra H, Brun A, Maassen CB, et al.  
1529 Bead-based suspension array for simultaneous detection of antibodies against the Rift  
1530 Valley fever virus nucleocapsid and Gn glycoprotein. *J Virol Methods*. 2012;183(2):99-  
1531 105. doi: 10.1016/j.jviromet.2012.03.008.
- 1532
- 1533 77. Petrova V, Kristiansen P, Norheim G, Yimer SA. Rift valley fever: diagnostic  
1534 challenges and investment needs for vaccine development. *BMJ Glob Health*.  
1535 2020;5(8). Epub 2020/08/21. doi: 10.1136/bmjgh-2020-002694.
- 1536
- 1537 78. Beechler BR, Manore CA, Reininghaus B, O'Neal D, Gorsich EE, Ezenwa VO, et al.  
1538 Enemies and turncoats: bovine tuberculosis exposes pathogenic potential of Rift Valley  
1539 fever virus in a common host, African buffalo (*Syncerus caffer*). *Proc Biol Sci*.  
1540 2015;282(1805). Epub 2015/03/20. doi: 10.1098/rspb.2014.2942.
- 1541
- 1542 79. Capobianco Dondona A, Aschenborn O, Pinoni C, Di Gialleonardo L, Maseke A,  
1543 Bortone G, et al. Rift Valley fever virus among wild ruminants, Etosha National Park,  
1544 Namibia, 2011. *Emerg Infect Dis*. 2016;22(1):128-130. doi: 10.3201/eid2201.150725.
- 1545
- 1546 80. Sindato C, Swai ES, Karimuribo ED, Dautu G, Pfeiffer DU, Mboera LEG, et al.  
1547 Spatial distribution of non-clinical Rift Valley fever viral activity in domestic and wild  
1548 ruminants in northern Tanzania. *Tanzania Veterinary Journal*. 2013;28 (Special):21-38.
- 1549
- 1550 81. Selmi R, Mamlouk A, Ben Said M, Ben Yahia H, Abdelaali H, Ben Chehida F, et al.  
1551 First serological evidence of the Rift Valley fever Phlebovirus in Tunisian camels. *Acta*  
1552 *Trop*. 2020;207:105462. Epub 2020/04/24. doi: 10.1016/j.actatropica.2020.105462.
- 1553
- 1554 82. Di Nardo A, Rossi D, Saleh SM, Lejlifa SM, Hamdi SJ, Di Gennaro A, et al.  
1555 Evidence of Rift Valley fever seroprevalence in the Sahrawi semi-nomadic pastoralist  
1556 system, Western Sahara. *BMC Vet Res*. 2014;10:92. Epub 2014/04/25. doi:  
1557 10.1186/1746-6148-10-92.
- 1558



- 1559 83. Kanouté YB, Gragnon BG, Schindler C, Bonfoh B, Schelling E. Epidemiology of  
1560 brucellosis, Q Fever and Rift Valley fever at the human and livestock interface in  
1561 northern Côte d'Ivoire. *Acta Trop.* 2017;165:66-75. Epub 2016/02/24. doi:  
1562 10.1016/j.actatropica.2016.02.012.
- 1563  
1564 84. Andayi F, Charrel RN, Kieffer A, Richet H, Pastorino B, Leparco-Goffart I, et al. A  
1565 sero-epidemiological study of arboviral fevers in Djibouti, Horn of Africa. *PLoS Negl*  
1566 *Trop Dis.* 2014;8(12):e3299. Epub 2014/12/17. doi: 10.1371/journal.pntd.0003299.
- 1567  
1568 85. Umuhoza T, Berkvens D, Gafarasi I, Rukelibuga J, Mushonga B, Biryomumaisho S.  
1569 Seroprevalence of Rift Valley fever in cattle along the Akagera-Nyabarongo rivers,  
1570 Rwanda. *J S Afr Vet Assoc.* 2017;88(0):e1-e5. doi: 10.4102/jsava.v88i0.1379.
- 1571  
1572 86. Dutuze MF, Ingabire A, Gafarasi I, Uwituze S, Nzayirambaho M, Christofferson RC.  
1573 Identification of Bunyamwera and possible other Orthobunyavirus infections and  
1574 disease in cattle during a Rift Valley fever outbreak in Rwanda in 2018. *Am J Trop Med*  
1575 *Hyg.* 2020;103(1):183-189. Epub 2020/04/22. doi: 10.4269/ajtmh.19-0596.
- 1576  
1577 87. Bonney JH, Osei-Kwasi M, Adiku TK, Barnor JS, Amesiya R, Kubio C, et al.  
1578 Hospital-based surveillance for viral hemorrhagic fevers and hepatitis in Ghana.  
1579 *PLoS Negl Trop Dis.* 2013;7(9):e2435. Epub 2013/09/27. doi:  
1580 10.1371/journal.pntd.0002435.
- 1581  
1582 88. Bird BH, Githinji JW, Macharia JM, Kasiiti JL, Muriithi RM, Gacheru SG, et al.  
1583 Multiple virus lineages sharing recent common ancestry were associated with a large  
1584 Rift Valley fever outbreak among livestock in Kenya during 2006-2007. *J Virol.*  
1585 2008;82(22):11152-11166. doi: 10.1128/JVI.01519-08.
- 1586  
1587 89. Miller BR, Godsey MS, Crabtree MB, Savage HM, Al-Mazrao Y, Al-Jeffri MH, et al.  
1588 Isolation and genetic characterization of Rift Valley fever virus from *Aedes vexans*  
1589 *arabiensis*, Kingdom of Saudi Arabia. *Emerg Infect Dis.* 2002;8(12):1492-1494. Epub  
1590 2002/12/25. doi: 10.3201/eid0812.020194.
- 1591  
1592 90. Nderitu L, Lee JS, Omolo J, Omulo S, O'Guinn ML, Hightower A, et al. Sequential  
1593 Rift Valley fever outbreaks in eastern Africa caused by multiple lineages of the virus. *J*  
1594 *Infect Dis.* 2011;203(5):655-665. doi: 10.1093/infdis/jjq004.
- 1595  
1596 91. Maquart M, Pascalis H, Abdouroihmane S, Roger M, Abdourahime F, Cardinale E,  
1597 et al. Phylogeographic reconstructions of a Rift Valley fever virus strain reveals  
1598 transboundary animal movements from eastern continental Africa to the Union of the



- 1599 Comoros. *Transbound Emerg Dis.* 2016;63(2):e281-285. Epub 2014/09/13. doi:  
1600 10.1111/tbed.12267.
- 1601
- 1602 92. Ratovonjato J, Olive MM, Tantely LM, Andrianaivolambo L, Tata E, Razainirina J, et  
1603 al. Detection, isolation, and genetic characterization of Rift Valley fever virus from  
1604 *Anopheles (Anopheles) coustani*, *Anopheles (Anopheles) squamosus*, and *Culex*  
1605 (*Culex*) *antennatus* of the Haute Matsiatra region, Madagascar. *Vector Borne Zoonotic*  
1606 *Dis.* 2011;11(6):753-759. Epub 2010/10/30. doi: 10.1089/vbz.2010.0031.
- 1607
- 1608 93. Andriamandimby SF, Randrianarivo-Solofoniaina AE, Jeanmaire EM,  
1609 Ravololomanana L, Razafimanantsoa LT, Rakotojoelinandrasana T, et al. Rift Valley  
1610 fever during rainy seasons, Madagascar, 2008 and 2009. *Emerg Infect Dis.*  
1611 2010;16(6):963-970. doi: 10.3201/eid1606.091266.
- 1612
- 1613 94. Faye O, Ba H, Ba Y, Freire CC, Faye O, Ndiaye O, et al. Reemergence of Rift  
1614 Valley fever, Mauritania, 2010. *Emerg Infect Dis.* 2014;20(2):300-303. Epub 2014/01/23.  
1615 doi: 10.3201/eid2002.130996.
- 1616
- 1617 95. Sow A, Faye O, Ba Y, Diallo D, Fall G, Faye O, et al. Widespread Rift Valley fever  
1618 emergence in Senegal in 2013-2014. *Open Forum Infect Dis.* 2016;3(3):ofw149. Epub  
1619 2016/10/06. doi: 10.1093/ofid/ofw149.
- 1620
- 1621 96. Sow A, Faye O, Ba Y, Ba H, Diallo D, Faye O, et al. Rift Valley fever outbreak,  
1622 southern Mauritania, 2012. *Emerg Infect Dis.* 2014;20(2):296-299. Epub 2014/01/23.  
1623 doi: 10.3201/eid2002.131000.
- 1624
- 1625 97. Lagare A, Fall G, Ibrahim A, Ousmane S, Sadio B, Abdoulaye M, et al. First  
1626 occurrence of Rift Valley fever outbreak in Niger, 2016. *Vet Med Sci.* 2019;5(1):70-78.  
1627 Epub 2018/11/10. doi: 10.1002/vms3.135.
- 1628
- 1629 98. Grobbelaar AA, Weyer J, Leman PA, Kemp A, Paweska JT, Swanepoel R.  
1630 Molecular epidemiology of Rift Valley fever virus. *Emerg Infect Dis.* 2011;17(12):2270-  
1631 2276. Epub 2011/12/17. doi: 10.3201/eid1712.111035.
- 1632
- 1633 99. van Schalkwyk A, Gwala S, Schuck KN, Quan M, Davis AS, Romito M, et al.  
1634 Retrospective phylogenetic analyses of formalin-fixed paraffin-embedded samples from  
1635 the 2011 Rift Valley fever outbreak in South Africa, through sequencing of targeted  
1636 regions. *J Virol Methods.* 2020;287:114003. Epub 2020/11/10. doi:  
1637 10.1016/j.jviromet.2020.114003.
- 1638

- 1639 100. van Schalkwyk A, Romito M. Genomic characterization of Rift Valley fever virus,  
1640 South Africa, 2018. *Emerg Infect Dis.* 2019;25(10):1979-1981. Epub 2019/09/21. doi:  
1641 10.3201/eid2510.181748.
- 1642
- 1643 101. Liu W, Sun FJ, Tong YG, Zhang SQ, Cao WC. Rift Valley fever virus imported into  
1644 China from Angola. *Lancet Infect Dis.* 2016;16(11):1226. Epub 2016/10/30. doi:  
1645 10.1016/s1473-3099(16)30401-7.
- 1646
- 1647 102. Grobbelaar AA, Weyer J, Leman P, Kemp A, Paweska JT. Phylogeny of Rift Valley  
1648 fever virus isolates recovered from humans during 2008-2011 disease outbreaks in  
1649 South Africa. *International Journal of Infectious Diseases.* 2014;21:224-224. doi:  
1650 10.1016/j.ijid.2014.03.887.
- 1651
- 1652 103. Bett B, Said MY, Sang R, Bukachi S, Wanyoike S, Kifugo SC, et al. Effects of flood  
1653 irrigation on the risk of selected zoonotic pathogens in an arid and semi-arid area in the  
1654 eastern Kenya. *PLoS One.* 2017;12(5). doi: 10.1371/journal.pone.0172626.
- 1655
- 1656 104. LaBeaud AD, Muiruri S, Sutherland LJ, Dahir S, Gildengorin G, Morrill J, et al.  
1657 Postepidemic analysis of Rift Valley fever virus transmission in northeastern Kenya: a  
1658 village cohort study. *PLoS Negl Trop Dis.* 2011;5(8):e1265. doi:  
1659 10.1371/journal.pntd.0001265.
- 1660
- 1661 105. Arishi H, Ageel A, Rahman MA, Al Hazmi A, Arishi AR, Ayoola B, et al. Update:  
1662 Outbreak of Rift Valley fever - Saudi Arabia, August-November 2000 (Reprinted from  
1663 *MMWR*, vol 49, pg 982-986, 2000). *Journal of the American Medical Association.*  
1664 2000;284(23):2989-2990.
- 1665
- 1666 106. Dobson MC, Kellendorfer JM, Williams RE, Kwarteng A, editors. SAR-based land-  
1667 cover classification of Kuwait. *International Geoscience and Remote Sensing*  
1668 *Symposium*; 2000; Honolulu.
- 1669
- 1670 107. Outbreak of Rift Valley fever, Yemen, August-October 2000. *Wkly Epidemiol Rec.*  
1671 2000;75(48):392-395. Epub 2001/01/06.
- 1672
- 1673 108. Hanafi HA, Fryauff DJ, Saad MD, Soliman AK, Mohareb EW, Medhat I, et al. Virus  
1674 isolations and high population density implicate *Culex antennatus* (Becker) (Diptera:  
1675 Culicidae) as a vector of Rift Valley fever virus during an outbreak in the Nile Delta of  
1676 Egypt. *Acta Trop.* 2011;119(2-3):119-124. Epub 2011/05/17. doi:  
1677 10.1016/j.actatropica.2011.04.018.
- 1678

- 1679 109. Faye O, Diallo M, Diop D, Bezeid OE, Bâ H, Niang M, et al. Rift Valley fever  
1680 outbreak with East-Central African virus lineage in Mauritania, 2003. *Emerg Infect Dis.*  
1681 2007;13(7):1016-1023. Epub 2008/01/25. doi: 10.3201/eid1307.061487.
- 1682
- 1683 110. Sindato C, Karimuribo ED, Pfeiffer DU, Mboera LE, Kivaria F, Dautu G, et al.  
1684 Spatial and temporal pattern of Rift Valley fever outbreaks in Tanzania; 1930 to 2007.  
1685 *PLoS One.* 2014;9(2):e88897. Epub 2014/03/04. doi: 10.1371/journal.pone.0088897.
- 1686
- 1687 111. El Mamy AB, Baba MO, Barry Y, Isselmou K, Dia ML, El Kory MO, et al.  
1688 Unexpected Rift Valley fever outbreak, northern Mauritania. *Emerg Infect Dis.*  
1689 2011;17(10):1894-1896. Epub 2011/10/18. doi: 10.3201/eid1710.110397.
- 1690
- 1691 112. El Mamy AB, Kane Y, El Arbi AS, Barry Y, Bernard C, Lancelot R, et al. L'épidémie  
1692 de la fièvre de la Vallée du Rift en 2012 en Mauritanie. *Revue Africaine de Santé et*  
1693 *Productions Animales.* 2014;12(3-4):169-173.
- 1694
- 1695 113. Shoemaker T, Balinandi S, Nyakarahuka L, Ojwang J, Tumusiime A, Mulei S, et al.  
1696 First laboratory confirmation of an outbreak of Rift Valley fever virus in 50 Years in  
1697 Kabale District, southwestern Uganda. *American Journal of Tropical Medicine and*  
1698 *Hygiene.* 2017;95(5):437-437.
- 1699
- 1700 114. Hassan A, Muturi M, Mwatondo A, Omolo J, Bett B, Gikundi S, et al.  
1701 Epidemiological investigation of a Rift Valley fever outbreak in humans and livestock in  
1702 Kenya, 2018. *Am J Trop Med Hyg.* 2020;103(4):1649-1655. Epub 2020/08/05. doi:  
1703 10.4269/ajtmh.20-0387.
- 1704
- 1705 115. Youssouf H, Subiros M, Denetiere G, Collet L, Dommergues L, Pauvert A, et al.  
1706 Rift Valley fever outbreak, Mayotte, France, 2018-2019. *Emerg Infect Dis.*  
1707 2020;26(4):769-772. Epub 2020/03/19. doi: 10.3201/eid2604.191147.
- 1708
- 1709 116. van Vuren PJ, Kgaladi J, Patharoo V, Ohaebosim P, Msimang V, Nyokong B, et al.  
1710 Human cases of Rift Valley fever in South Africa, 2018. *Vector-Borne and Zoonotic*  
1711 *Diseases.* 2018;18(12):713-715. doi: 10.1089/vbz.2018.2357.
- 1712
- 1713 117. Youssef HM, Ghoneim MA, al. e. Recent trends for diagnosis of Rift Valley  
1714 fever in animals and mosquitoes in Egypt with special reference to the carrier.  
1715 *Global Veterinaria.* 2008;2(1).
- 1716

- 1717 118. Jeffries CL, Tantely LM, Raharimalala FN, Hurn E, Boyer S, Walker T. Diverse  
1718 novel resident *Wolbachia* strains in Culicine mosquitoes from Madagascar. Scientific  
1719 Reports. 2018;8. doi: 10.1038/s41598-018-35658-z.
- 1720
- 1721 119. Ndiaye EH, Diallo D, Fall G, Ba Y, Faye O, Dia I, et al. Arboviruses isolated from  
1722 the Barkedji mosquito-based surveillance system, 2012-2013. BMC Infect Dis.  
1723 2018;18(1):642. Epub 2018/12/14. doi: 10.1186/s12879-018-3538-2.
- 1724
- 1725 120. Abdelgadir DM, Bashab HMM, Mohamed RAE, Abuelmaali SA. Risk factor  
1726 analysis for outbreak of Rift Valley fever in Khartoum State of Sudan. Journal of  
1727 Entomological Science. 2010;45(3):239-251. doi: 10.18474/0749-8004-45.3.239.
- 1728
- 1729 121. Mbanzulu KM, Mboera LEG, Luzolo FK, Wumba R, Misinzo G, Kimera SI.  
1730 Mosquito-borne viral diseases in the Democratic Republic of the Congo: a review.  
1731 Parasit Vectors. 2020;13(1):103. Epub 2020/02/28. doi: 10.1186/s13071-020-3985-7.
- 1732
- 1733 122. Mohamed RAE, Mohamed N, Aleanizy FS, Alqahtani FY, Al Khalaf A, Al-Keridis  
1734 LA. Investigation of hemorrhagic fever viruses inside wild populations of ticks: One of  
1735 the pioneer studies in Saudi Arabia. Asian Pacific Journal of Tropical Disease.  
1736 2017;7:299-303.
- 1737
- 1738 123. Mohamed M, Mosha F, Mghamba J, Zaki SR, Shieh WJ, Paweska J, et al.  
1739 Epidemiologic and clinical aspects of a Rift Valley fever outbreak in humans in  
1740 Tanzania, 2007. Am J Trop Med Hyg. 2010;83(2 Suppl):22-27. doi:  
1741 10.4269/ajtmh.2010.09-0318.
- 1742
- 1743 124. LaBeaud AD, Pfeil S, Muiruri S, Dahir S, Sutherland LJ, Traylor Z, et al. Factors  
1744 associated with severe human Rift Valley fever in Sangailu, Garissa County, Kenya.  
1745 PLoS Negl Trop Dis. 2015;9(3):e0003548. Epub 2015/03/13. doi:  
1746 10.1371/journal.pntd.0003548.
- 1747
- 1748 125. Anyangu AS, Gould LH, Sharif SK, Nguku PM, Omolo JO, Mutonga D, et al. Risk  
1749 factors for severe Rift Valley fever infection in Kenya, 2007. Am J Trop Med Hyg.  
1750 2010;83(2 Suppl):14-21. doi: 10.4269/ajtmh.2010.09-0293.
- 1751
- 1752 126. Seufi AM, Galal FH. Role of *Culex* and *Anopheles* mosquito species as potential  
1753 vectors of Rift Valley fever virus in Sudan outbreak, 2007. BMC Infect Dis. 2010;10:65.  
1754 Epub 2010/03/13. doi: 10.1186/1471-2334-10-65.
- 1755

- 1756 127. Oyas H, Holmstrom L, Kemunto NP, Muturi M, Mwatondo A, Osoro E, et al.  
1757 Enhanced surveillance for Rift Valley fever in livestock during El Niño rains and threat of  
1758 RVF outbreak, Kenya, 2015-2016. *PLoS Negl Trop Dis*. 2018;12(4):e0006353. Epub  
1759 2018/04/27. doi: 10.1371/journal.pntd.0006353.
- 1760  
1761 128. Bashir RSE, Hassan OA. A One Health perspective to identify environmental  
1762 factors that affect Rift Valley fever transmission in Gezira state, Central Sudan. *Tropical*  
1763 *Medicine and Health*. 2019;47(1). doi: 10.1186/s41182-019-0178-1.
- 1764  
1765 129. van Vuren PJ, Shalekoff S, Grobbelaar AA, Archer BN, Thomas J, Tiemessen CT,  
1766 et al. Serum levels of inflammatory cytokines in Rift Valley fever patients are indicative  
1767 of severe disease. *Virology Journal*. 2015;12. doi: 10.1186/s12985-015-0392-3.
- 1768  
1769 130. Outbreak news. Rift Valley fever, Kenya. *Wkly Epidemiol Rec*. 2007;82(3):17-18.  
1770 Epub 2007/01/24.
- 1771  
1772 131. Madani TA, Al-Mazrou YY, Al-Jeffri MH, Mishkhas AA, Al-Rabeah AM, Turkistani  
1773 AM, et al. Rift Valley fever epidemic in Saudi Arabia: epidemiological, clinical, and  
1774 laboratory characteristics. *Clin Infect Dis*. 2003;37(8):1084-1092. doi: 10.1086/378747.
- 1775  
1776 132. Njenga MK, Paweska J, Wanjala R, Rao CY, Weiner M, Omballa V, et al. Using a  
1777 field quantitative real-time PCR test to rapidly identify highly viremic rift valley fever  
1778 cases. *J Clin Microbiol*. 2009;47(4):1166-1171. Epub 2009/01/28. doi:  
1779 10.1128/jcm.01905-08.
- 1780  
1781 133. Chengula AA, Kasanga CJ, Mdegela RH, Sallu R, Yongolo M. Molecular detection  
1782 of Rift Valley fever virus in serum samples from selected areas of Tanzania. *Trop Anim*  
1783 *Health Prod*. 2014;46(4):629-634. Epub 2014/01/28. doi: 10.1007/s11250-014-0540-6.
- 1784  
1785 134. Bett B, Lindahl J, Sang R, Wainaina M, Kairu-Wanyoike S, Bukachi S, et al.  
1786 Association between Rift Valley fever virus seroprevalences in livestock and humans  
1787 and their respective intra-cluster correlation coefficients, Tana River County, Kenya.  
1788 *Epidemiology and Infection*. 2019;147. doi: 10.1017/S0950268818003242.
- 1789  
1790 135. Nicolas G, Chevalier V, Tantely LM, Fontenille D, Durand B. A spatially explicit  
1791 metapopulation model and cattle trade analysis suggests key determinants for the  
1792 recurrent circulation of Rift Valley fever virus in a pilot area of Madagascar highlands.  
1793 *PLoS Negl Trop Dis*. 2014;8(12):e3346. doi: 10.1371/journal.pntd.0003346.
- 1794

- 1795 136. Metras R, Cavalerie L, Dommergues L, Merot P, Edmunds WJ, Keeling MJ, et al.  
1796 The epidemiology of Rift Valley fever in Mayotte: insights and perspectives from 11  
1797 years of data. *Plos Neglected Tropical Diseases*. 2016;10(6). doi:  
1798 10.1371/journal.pntd.0004783.
- 1799  
1800 137. Alhaj M. Surveillance study on Rift Valley fever in Jazan region, Saudi Arabia. *Int J*  
1801 *Adv Sci Tech Res*. 2015;5(4):1-13.
- 1802  
1803 138. Ngoshe YB, Avenant A, Rostal MK, Karesh WB, Paweska JT, Bagge W, et al.  
1804 Patterns of Rift Valley fever virus seropositivity in domestic ruminants in central South  
1805 Africa four years after a large outbreak. *Scientific Reports*. 2020;10(1). doi:  
1806 10.1038/s41598-020-62453-6.
- 1807  
1808 139. Moiane B, Mapaco L, Thompson P, Berg M, Albihn A, Fafetine J. High  
1809 seroprevalence of Rift Valley fever phlebovirus in domestic ruminants and African  
1810 Buffaloes in Mozambique shows need for intensified surveillance. *Infect Ecol Epidemiol*.  
1811 2017;7(1):1416248. Epub 2018/01/13. doi: 10.1080/20008686.2017.1416248.
- 1812  
1813 140. Caron A, Cornelis D, Foggin C, Hofmeyr M, de Garine-Wichatitsky M. African  
1814 Buffalo movement and zoonotic disease risk across transfrontier conservation areas,  
1815 Southern Africa. *Emerg Infect Dis*. 2016;22(2):277-280. Epub 2016/01/27. doi:  
1816 10.3201/eid2202.140864.
- 1817  
1818 141. Byomi AM, Samaha HA, Zidan SA, Hadad GA. Some associated risk factors with  
1819 the occurrence of Rift Valley fever in animals and man in certain localities of Nile delta,  
1820 Egypt. *Assiut Veterinary Medical Journal*. 2015;61:10-17.
- 1821  
1822 142. Mohamed AM, Ashshi AM, Asghar AH, Abd El-Rahim IH, El-Shemi AG, Zafar T.  
1823 Seroepidemiological survey on Rift Valley fever among small ruminants and their close  
1824 human contacts in Makkah, Saudi Arabia, in 2011. *Rev Sci Tech*. 2014;33(3):903-915.  
1825 doi: 10.20506/rst.33.3.2328.
- 1826  
1827 143. Wensman JJ, Lindahl J, Wachtmeister N, Torsson E, Gwakisa P, Kasanga C, et  
1828 al. A study of Rift Valley fever virus in Morogoro and Arusha regions of Tanzania -  
1829 serology and farmers' perceptions. *Infect Ecol Epidemiol*. 2015;5:30025. doi:  
1830 10.3402/iee.v5.30025.
- 1831  
1832 144. Elfadil AA, Hasab-Allah KA, Dafa-Allah OM. Factors associated with Rift Valley  
1833 fever in south-west Saudi Arabia. *Rev Sci Tech*. 2006;25(3):1137-1145.
- 1834



- 1835 145. Mdlulwa Z, Ngwane CB. Evaluating the impact of 2010 Rift Valley fever outbreaks  
1836 on sheep numbers in three provinces of South Africa. . African Journal of Agricultural  
1837 Research. 2017;12(11):979–986.
- 1838  
1839 146. Mroz C, Gwida M, El-Ashker M, Ziegler U, Homeier-Bachmann T, Eiden M, et al.  
1840 Rift Valley fever virus infections in Egyptian cattle and their prevention. *Transbound*  
1841 *Emerg Dis*. 2017;64(6):2049-2058. Epub 2017/01/25. doi: 10.1111/tbed.12616.
- 1842  
1843 147. Abbas B, Yousif MA, M. NH. Animal health constraints to livestock exports from  
1844 the Horn of Africa. *Rev Sci Tech*. 2014;33(3): 711-721.
- 1845  
1846 148. Mohamed AM, Ghazi H, Ashshi AM, Faidah HS, Clinical EIA. Serological survey of  
1847 Rift Valley fever among sacrifice animals in holy Mecca during pilgrimage season. . *Int J*  
1848 *Trop Med*. 2011;6(4):85–89.
- 1849  
1850 149. Tong C, Javelle E, Grard G, Dia A, Lacrosse C, Fourié T, et al. Tracking Rift Valley  
1851 fever: From Mali to Europe and other countries, 2016. *Euro Surveill*. 2019;24(8). Epub  
1852 2019/02/28. doi: 10.2807/1560-7917.es.2019.24.8.1800213.
- 1853  
1854 150. Liu B, Ma J, Jiao Z, Gao X, Xiao J, Wang H. Risk assessment for the Rift Valley  
1855 fever occurrence in China: Special concern in south-west border areas. *Transbound*  
1856 *Emerg Dis*. 2020. Epub 2020/06/23. doi: 10.1111/tbed.13695.
- 1857  
1858 151. Grossi-Soyster EN, LaBeaud AD. Rift Valley fever: Important considerations for  
1859 risk mitigation and future outbreaks. *Trop Med Infect Dis*. 2020;5(2). doi:  
1860 10.3390/tropicalmed5020089.
- 1861  
1862 152. O'Hearn AE, Voorhees MA, Fetterer DP, Wauquier N, Coomber MR, Bangura J, et  
1863 al. Serosurveillance of viral pathogens circulating in West Africa. *Viol J*.  
1864 2016;13(1):163. Epub 2016/10/08. doi: 10.1186/s12985-016-0621-4.
- 1865  
1866 153. LaBeaud AD, Ochiai Y, Peters CJ, Muchiri EM, King CH. Spectrum of Rift Valley  
1867 fever virus transmission in Kenya: Insights from three distinct regions. *American Journal*  
1868 *of Tropical Medicine and Hygiene*. 2007;76(5):795-800. doi:  
1869 10.4269/ajtmh.2007.76.795.
- 1870  
1871 154. Grossi-Soyster EN, Banda T, Teng CY, Muchiri EM, Mungai PL, Mutuku FM, et al.  
1872 Rift Valley fever seroprevalence in coastal Kenya. *Am J Trop Med Hyg*. 2017;97(1):115-  
1873 120. Epub 2017/07/19. doi: 10.4269/ajtmh.17-0104.



- 1874  
1875 155. Cook EAJ, Grossi-Soyster EN, de Glanville WA, Thomas LF, Kariuki S, Bronsvort  
1876 BMD, et al. The sero-epidemiology of Rift Valley fever in people in the Lake Victoria  
1877 Basin of western Kenya. *Plos Neglected Tropical Diseases*. 2017;11(7). doi:  
1878 10.1371/journal.pntd.0005731.
- 1879  
1880 156. Gray GC, Anderson BD, LaBeaud AD, Heraud JM, Fevre EM, Andriamandimby  
1881 SF, et al. Seroepidemiological study of interepidemic Rift Valley fever virus infection  
1882 among persons with intense ruminant exposure in Madagascar and Kenya. *Am J Trop*  
1883 *Med Hyg*. 2015;93(6):1364-1370. doi: 10.4269/ajtmh.15-0383.
- 1884  
1885 157. LaBeaud AD, Bashir F, King CH. Measuring the burden of arboviral diseases: the  
1886 spectrum of morbidity and mortality from four prevalent infections. *Population Health*  
1887 *Metrics*. 2011;9. doi: 10.1186/1478-7954-9-1.
- 1888  
1889 158. Muiruri S, Kabiru EW, Muchiri EM, Hussein H, Kagonda F, LaBeaud AD, et al.  
1890 Cross-sectional survey of Rift Valley fever virus exposure in Bodhei village located in a  
1891 transitional coastal forest habitat in Lamu County, Kenya. *Am J Trop Med Hyg*.  
1892 2015;92(2):394-400. Epub 2014/12/24. doi: 10.4269/ajtmh.14-0440.
- 1893  
1894 159. Nanyingi MO, Munyua P, Kiama SG, Muchemi GM, Thumbi SM, Bitek AO, et al. A  
1895 systematic review of Rift Valley fever epidemiology 1931-2014. *Infect Ecol Epidemiol*.  
1896 2015;5:28024. Epub 2015/08/04. doi: 10.3402/iee.v5.28024.
- 1897  
1898 160. Jori F, Godfroid J, Michel AL, Potts AD, Jaumally MR, Sauzier J, et al. An  
1899 assessment of zoonotic and production limiting pathogens in rusa deer (*Cervus*  
1900 *timorensis rusa*) from Mauritius. *Transbound Emerg Dis*. 2014;61 Suppl 1:31-42. doi:  
1901 10.1111/tbed.12206.
- 1902  
1903 161. Elfving K, Shakely D, Andersson M, Baltzell K, Ali AS, Bachelard M, et al. Acute  
1904 uncomplicated febrile illness in children aged 2-59 months in Zanzibar - aetiologies,  
1905 antibiotic treatment and outcome. *PLoS One*. 2016;11(1):e0146054. Epub 2016/01/29.  
1906 doi: 10.1371/journal.pone.0146054.
- 1907  
1908 162. Nicolas G, Durand B, Duboz R, Rakotondravao R, Chevalier V. Description and  
1909 analysis of the cattle trade network in the Madagascar highlands: potential role in the  
1910 diffusion of Rift Valley fever virus. *Acta Trop*. 2013;126(1):19-27. doi:  
1911 10.1016/j.actatropica.2012.12.013.
- 1912

- 1913 163. Abdo-Salem S, Tran A, Grosbois V, Gerbier G, Al-Qadasi M, Saeed K, et al. Can  
1914 environmental and socioeconomic factors explain the recent emergence of Rift Valley  
1915 fever in Yemen, 2000-2001? *Vector Borne Zoonotic Dis.* 2011;11(6):773-779. Epub  
1916 2011/02/03. doi: 10.1089/vbz.2010.0084.
- 1917  
1918 164. Xiao Y, Beier JC, Cantrell RS, Cosner C, DeAngelis DL, Ruan S. Modelling the  
1919 effects of seasonality and socioeconomic impact on the transmission of Rift Valley fever  
1920 virus. *PLoS Negl Trop Dis.* 2015;9(1):e3388. Epub 2015/01/09. doi:  
1921 10.1371/journal.pntd.0003388.
- 1922  
1923 165. Apolloni A, Nicolas G, Coste C, El Mamy AB, Yahya B, El Arbi AS, et al. Towards  
1924 the description of livestock mobility in Sahelian Africa: Some results from a survey in  
1925 Mauritania. *PLoS One.* 2018;13(1). doi: 10.1371/journal.pone.0191565.
- 1926  
1927 166. Bergren NA, Borland EM, Hartman DA, Kading RC. Laboratory demonstration of  
1928 the vertical transmission of Rift Valley fever virus by *Culex tarsalis* mosquitoes. *PLoS*  
1929 *Negl Trop Dis.* 2021;15(3):e0009273. doi: 10.1371/journal.pntd.0009273.
- 1930  
1931 167. Antonis AF, Kortekaas J, Kant J, Vloet RP, Vogel-Brink A, Stockhofe N, et al.  
1932 Vertical transmission of Rift Valley fever virus without detectable maternal viremia.  
1933 *Vector Borne Zoonotic Dis.* 2013;13(8):601-606. doi: 10.1089/vbz.2012.1160.
- 1934  
1935 168. Adam I, Karsany MS. Case report: Rift Valley fever with vertical transmission in a  
1936 pregnant Sudanese woman. *J Med Virol.* 2008;80(5):929. Epub 2008/03/25. doi:  
1937 10.1002/jmv.21132.
- 1938  
1939 169. Arishi HM, Aqeel AY, Al Hazmi MM. Vertical transmission of fatal Rift Valley fever  
1940 in a newborn. *Ann Trop Paediatr.* 2006;26(3):251-253. doi:  
1941 10.1179/146532806X120363.
- 1942  
1943 170. Baudin M, Jumaa AM, Jomma HJE, Karsany MS, Bucht G, Näslund J, et al.  
1944 Association of Rift Valley fever virus infection with miscarriage in Sudanese women: a  
1945 cross-sectional study. *Lancet Glob Health.* 2016;4(11):e864-e871. Epub 2016/10/22.  
1946 doi: 10.1016/s2214-109x(16)30176-0.
- 1947  
1948 171. Pienaar NJ, Thompson PN. Temporal and spatial history of Rift Valley fever in  
1949 South Africa: 1950 to 2011. *Onderstepoort J Vet Res.* 2013;80(1):384. Epub  
1950 2013/05/31. doi: 10.4102/ojvr.v80i1.384.
- 1951

- 1952 172. Ndengu M, Matope G, Tivapasi M, Pfukenyi DM, Cetre-Sossah C, De Garine-  
1953 Wichatitsky M. Seroprevalence and associated risk factors of Rift Valley fever in cattle  
1954 and selected wildlife species at the livestock/wildlife interface areas of Gonarezhou  
1955 National Park, Zimbabwe. *Onderstepoort J Vet Res.* 2020;87(1):e1-e7. Epub  
1956 2020/05/07. doi: 10.4102/ojvr.v87i1.1731.
- 1957  
1958 173. Nyakarahuka L, de St Maurice A, Purpura L, Ervin E, Balinandi S, Tumusiime A, et  
1959 al. Prevalence and risk factors of Rift Valley fever in humans and animals from Kabale  
1960 district in Southwestern Uganda, 2016. *PLoS Negl Trop Dis.* 2018;12(5):e0006412.  
1961 Epub 2018/05/04. doi: 10.1371/journal.pntd.0006412.
- 1962  
1963 174. FAO. Rift Valley fever vaccine development, progress and constraints.  
1964 *Proceedings of the GF-TADs meeting, January 2011. Rome, Italy: 2011.*
- 1965  
1966 175. Bird BH, Nichol ST. Breaking the chain: Rift Valley fever virus control via livestock  
1967 vaccination. *Curr Opin Virol.* 2012;2(3):315-323. Epub 2012/04/03. doi:  
1968 10.1016/j.coviro.2012.02.017.
- 1969  
1970 176. Shoemaker TR, Nyakarahuka L, Balinandi S, Ojwang J, Tumusiime A, Mulei S, et  
1971 al. First laboratory-confirmed outbreak of human and animal Rift Valley fever virus in  
1972 Uganda in 48 years. *Am J Trop Med Hyg.* 2019;100(3):659-671. Epub 2019/01/25. doi:  
1973 10.4269/ajtmh.18-0732.
- 1974  
1975 177. Archer BN, Weyer J, Paweska J, Nkosi D, Leman P, Tint KS, et al. Outbreak of  
1976 Rift Valley fever affecting veterinarians and farmers in South Africa, 2008. *S Afr Med J.*  
1977 2011;101(4):263-266. Epub 2011/07/27. doi: 10.7196/samj.4544.
- 1978  
1979 178. Tambo E, Olalubi OA, Sacko M. Rift Valley fever epidemic in Niger near border  
1980 with Mali. *Lancet Infectious Diseases.* 2016;16(12):1319-1320. doi: 10.1016/S1473-  
1981 3099(16)30477-7.
- 1982  
1983 179. Davies FG. Risk of a Rift Valley fever epidemic at the Haj in Mecca, Saudi Arabia.  
1984 *Rev Sci Tech.* 2006;25(1):137-147. doi: 10.20506/rst.25.1.1648.
- 1985  
1986 180. Krystosik A, Njoroge G, Odhiambo L, Forsyth JE, Mutuku F, LaBeaud AD. Solid  
1987 wastes provide breeding sites, burrows, and food for biological disease vectors, and  
1988 urban zoonotic reservoirs: A call to action for solutions-based research. *Front Public*  
1989 *Health.* 2019;7:405. doi: 10.3389/fpubh.2019.00405.
- 1990

- 1991 181. Salmon-Rousseau A, Piednoir E, Cattoir V, de La Blanchardiere A. Hajj-associated  
1992 infections. *Medecine Et Maladies Infectieuses*. 2016.
- 1993
- 1994 182. Cecilia H, Métras R, Fall AG, Lo MM, Lancelot R, Ezanno P. It's risky to wander in  
1995 September: Modelling the epidemic potential of Rift Valley fever in a Sahelian setting.  
1996 *Epidemics*. 2020;33:100409. Epub 2020/11/03. doi: 10.1016/j.epidem.2020.100409.
- 1997
- 1998 183. Obiero JPO, Onyando JO. Climate. *Developments in Earth Surface Processes*.  
1999 162013. p. 39-50.
- 2000
- 2001 184. Alhaji NB, Aminu J, Lawan MK, Babalobi OO, Ghali-Mohammed I, Odetokun IA.  
2002 Seropositivity and associated intrinsic and extrinsic factors for Rift Valley fever virus  
2003 occurrence in pastoral herds of Nigeria: a cross sectional survey. *BMC Vet Res*.  
2004 2020;16(1):243. Epub 2020/07/16. doi: 10.1186/s12917-020-02455-8.
- 2005
- 2006 185. Durand B, Lo Modou M, Tran A, Ba A, Sow F, Belkhiria J, et al. Rift Valley fever in  
2007 northern Senegal: A modelling approach to analyse the processes underlying virus  
2008 circulation recurrence. *Plos Neglected Tropical Diseases*. 2020;14(6). doi:  
2009 10.1371/journal.pntd.0008009.
- 2010
- 2011 186. Kakani S, LaBeaud AD, King CH. Planning for Rift Valley fever virus: use of  
2012 geographical information systems to estimate the human health threat of white-tailed  
2013 deer (*Odocoileus virginianus*)-related transmission. *Geospat Health*. 2010;5(1):33-43.  
2014 doi: 10.4081/gh.2010.185.
- 2015
- 2016 187. Wilson WC, Kim IJ, Trujillo JD, Sunwoo SY, Noronha LE, Urbaniak K, et al.  
2017 Susceptibility of white-tailed deer to Rift Valley fever virus. *Emerg Infect Dis*.  
2018 2018;24(9):1717-1719. Epub 2018/08/21. doi: 10.3201/eid2409.180265.
- 2019
- 2020 188. Bron GM, Strimbu K, Cecilia H, Lerch A, Moore SM, Tran Q, et al. Over 100 Years  
2021 of Rift Valley fever: A patchwork of data on pathogen spread and spillover. *Pathogens*.  
2022 2021;10(6). doi: 10.3390/pathogens10060708.
- 2023
- 2024 189. Schwarz NG, Girmann M, Randriamampionona N, Bialonski A, Maus D, Krefis AC,  
2025 et al. Seroprevalence of antibodies against chikungunya, dengue, and Rift Valley fever  
2026 viruses after febrile illness outbreak, Madagascar. *Emerg Infect Dis*. 2012;18(11):1780-  
2027 1786. doi: 10.3201/eid1811.111036.
- 2028

- 2029 190. Al-Qabati AG, Al-Afaleq AI. Cross-sectional, longitudinal and prospective  
2030 epidemiological studies of Rift Valley fever in Al-Hasa Oasis, Saudi Arabia. *Journal of*  
2031 *Animal and Veterinary Advances*. 2010;9(2):258-265.
- 2032  
2033 191. Grossi-Soyster EN, Lee J, King CH, LaBeaud AD. The influence of raw milk  
2034 exposures on Rift Valley fever virus transmission. *PLoS Negl Trop Dis*.  
2035 2019;13(3):e0007258. doi: 10.1371/journal.pntd.0007258.
- 2036  
2037 192. Gerken KN, Migliore E, Malumbo S, Shaita KN, Agola G, Fabre E, et al.  
2038 Seroprevalence of Rift Valley fever virus in urban Kenya: a potential public health  
2039 burden hiding in plain sight. *Am J Trop Med Hyg*. 2021:(in press).
- 2040  
2041 193. Cook EAJ, de Glanville WA, Thomas LF, Kariuki S, Bronsvoort B, Fevre EM.  
2042 Working conditions and public health risks in slaughterhouses in western Kenya. *BMC*  
2043 *Public Health*. 2017;17. doi: 10.1186/s12889-016-3923-y.
- 2044  
2045 194. Ikegami T, Balogh A, Nishiyama S, Lokugamage N, Saito TB, Morrill JC, et al.  
2046 Distinct virulence of Rift Valley fever phlebovirus strains from different genetic lineages  
2047 in a mouse model. *PLoS One*. 2017;12(12):e0189250. Epub 2017/12/22. doi:  
2048 10.1371/journal.pone.0189250.
- 2049  
2050 195. WHO. Factors that contributed to undetected spread of the Ebola virus and  
2051 impeded rapid containment Geneva, Switzerland: World Health Organization; 2015  
2052 [cited 2021 9/7/2021].
- 2053  
2054 196. de St Maurice A, Nyakarahuka L, Purpura L, Ervin E, Tumusiime A, Balinandi S, et  
2055 al. Notes from the field: Rift Valley fever response - Kabale District, Uganda, March  
2056 2016. *MMWR Morb Mortal Wkly Rep*. 2016;65(43):1200-1201. Epub 2016/11/05. doi:  
2057 10.15585/mmwr.mm6543a5.
- 2058  
2059 197. Hartley DM, Rinderknecht JL, Nipp TL, Clarke NP, Snowden GD, National Center  
2060 for Foreign A, et al. Potential effects of Rift Valley fever in the United States. *Emerg*  
2061 *Infect Dis*. 2011;17(8):e1. doi: 10.3201/eid1708.101088.
- 2062  
2063 198. Brugere-Picoux J, Chomel B. Importation of tropical diseases to Europe via  
2064 animals and animal products: risks and pathways. *Bulletin De L Academie Nationale De*  
2065 *Medecine*. 2009;193(8):1805-1819. doi: 10.1016/S0001-4079(19)32415-X.
- 2066  
2067 199. Cito F, Narcisi V, Danzetta ML, Iannetti S, Sabatino DD, Bruno R, et al. Analysis of  
2068 surveillance systems in place in European Mediterranean countries for West Nile virus

- 2069 (WNV) and Rift Valley fever (RVF). *Transbound Emerg Dis.* 2013;60 Suppl 2:40-44.  
2070 Epub 2014/03/05. doi: 10.1111/tbed.12124.
- 2071
- 2072 200. Nielsen SS, Alvarez J, Bicout DJ, Calistri P, Depner K, Drewe JA, et al. Rift Valley  
2073 fever - epidemiological update and risk of introduction into Europe. *EFSAJ.*  
2074 2020;18(3):e06041. Epub 2020/10/07. doi: 10.2903/j.efsa.2020.6041.
- 2075
- 2076 201. Rolin AI, Berrang-Ford L, Kulkarni MA. The risk of Rift Valley fever virus  
2077 introduction and establishment in the United States and European Union. *Emerg*  
2078 *Microbes Infect.* 2013;2(12):e81. Epub 2013/12/01. doi: 10.1038/emi.2013.81.
- 2079
- 2080 202. Zeller H, Marrama L, Sudre B, Van Bortel W, Warns-Petit E. Mosquito-borne  
2081 disease surveillance by the European Centre for Disease Prevention and Control. *Clin*  
2082 *Microbiol Infect.* 2013;19(8):693-698. Epub 2013/04/24. doi: 10.1111/1469-0691.12230.
- 2083
- 2084 203. Lagerqvist N, Moiane B, Mapaco L, Fafetine J, Vene S, Falk KI. Antibodies against  
2085 Rift Valley fever virus in cattle, Mozambique. *Emerg Infect Dis.* 2013;19(7):1177-1179.  
2086 Epub 2013/06/15. doi: 10.3201/eid1907.130332.
- 2087
- 2088 204. Abakar MF, Nare NB, Schelling E, Hattendorf J, Alfaroukh IO, Zinsstag J.  
2089 Seroprevalence of Rift Valley fever, Q Fever, and brucellosis in ruminants on the  
2090 southeastern shore of Lake Chad. *Vector-Borne and Zoonotic Diseases.*  
2091 2014;14(10):757-762. doi: 10.1089/vbz.2014.1585.
- 2092
- 2093 205. Consultative Group for RVFDS. Decision-support tool for prevention and control of  
2094 Rift Valley fever epizootics in the Greater Horn of Africa. *Am J Trop Med Hyg.*  
2095 2010;83(2 Suppl):75-85. doi: 10.4269/ajtmh.2010.83s2a03.
- 2096
- 2097 206. Shah MM, Ndenga BA, Mutuku FM, Vu DM, Grossi-Soyster EN, Okuta V, et al.  
2098 High dengue burden and circulation of 4 virus serotypes among children with  
2099 undifferentiated fever, Kenya, 2014-2017. *Emerg Infect Dis.* 2020;26(11):2638-2650.  
2100 doi: 10.3201/eid2611.200960.
- 2101
- 2102 207. Vu DM, Mutai N, Heath CJ, Vulule JM, Mutuku FM, Ndenga BA, et al.  
2103 Unrecognized dengue virus infections in children, western Kenya, 2014-2015. *Emerg*  
2104 *Infect Dis.* 2017;23(11):1915-1917. doi: 10.3201/eid2311.170807.
- 2105
- 2106 208. Hortion J, Mutuku FM, Eyherabide AL, Vu DM, Boothroyd DB, Grossi-Soyster EN,  
2107 et al. Acute flavivirus and alphavirus infections among children in two different areas of  
2108 Kenya, 2015. *Am J Trop Med Hyg.* 2019;100(1):170-173. doi: 10.4269/ajtmh.18-0297.



2109  
2110 209. Hertz JT, Munishi OM, Ooi EE, Howe S, Lim WY, Chow A, et al. Chikungunya and  
2111 dengue fever among hospitalized febrile patients in northern Tanzania. *Am J Trop Med*  
2112 *Hyg.* 2012;86(1):171-177. doi: 10.4269/ajtmh.2012.11-0393.

2113  
2114 210. Pepin M, Bouloy M, Bird BH, Kemp A, Paweska J. Rift Valley fever virus  
2115 (Bunyaviridae: Phlebovirus): an update on pathogenesis, molecular epidemiology,  
2116 vectors, diagnostics and prevention. *Vet Res.* 2010;41(6):61. Epub 2010/12/29. doi:  
2117 10.1051/vetres/2010033.

2118  
2119 211. Fakour S, Naserabadi S, Ahmadi E. The first positive serological study on Rift  
2120 Valley fever in ruminants of Iran. *J Vector Borne Dis.* 2017;54(4):348-352. Epub  
2121 2018/02/21. doi: 10.4103/0972-9062.225840.

2122  
2123 212. Amato L, Dente MG, Calistri P, Declich S. Integrated early warning surveillance:  
2124 Achilles' Heel of One Health? *Microorganisms.* 2020;8(1). doi:  
2125 10.3390/microorganisms8010084.

2126  
2127 213. Hassan OA, Ahlm C, Evander M. A need for One Health approach - lessons  
2128 learned from outbreaks of Rift Valley fever in Saudi Arabia and Sudan. *Infect Ecol*  
2129 *Epidemiol.* 2014;4. Epub 2014/02/08. doi: 10.3402/iee.v4.20710.

2130

## 2131 **Supporting Information**

2132 **Text:**

2133 **S1 Text.** Information sources and detailed scripts used in running the searches on the  
2134 online databases

2135 **Figures:**

2136 **S1 Figure.** Forest Plot for meta-analysis of the impact of butchering on odds of RVFV  
2137 exposure

2138 **S2 Figure.** Forest Plot for meta-analysis of the impact of sheltering animals on odds of  
2139 RVFV exposure



2140 **S3 Figure.** Forest Plot for meta-analysis of the impact of milking animals on odds of  
2141 RVFV exposure

2142 **Tables:**

2143 **S1 Table.** PRISMA checklist

2144 **S2 Table.** Listing of included studies with full citations

2145 **S3 Table.** Listing of excluded studies with full citations

2146 **S4 Table.** Listing by year of countries experiencing human or animal exposure to RVFV  
2147 during 1999-2021

2148 **S5 Table.** Listing of acute human cases reported during 1999-2021. Outbreaks are  
2149 indicated by year, country, region, and geographic location, with estimated population  
2150 size, incidence, and case fatality rates

2151 **S6 Table.** Studies of RVFV lineage distribution based on genetic sequence analysis

2152 **S7 Table.** 1999-2021 studies of local arthropod vector presence and RVFV infection

2153 **S8 Table.** Studies assessing human risk factors related to animal exposures and severe  
2154 RVFV disease

2155 **S9 Table.** Studies of the effects of socioeconomic status on human RVFV exposure risk


2156 **S10 Table.** Studies of the effects of occupation on human RVFV exposure risk

2157 **S11 Table.** Livestock factors related to animal RVFV exposure risk

2158 **S12 Table.** Wildlife anti-RVFV seroprevalence reported in included studies


2159 **S13 Table.** Local and national RVF surveillance systems reported in included studies

2160




**Identification of RVF occurrences via publication databases and registers**

**Identification of RVF occurrences via other methods**



**World Countries with RVFV exposure**


-  Negative surveys
-  Human exposure
-  Animal exposure
-  Human and animal exposure
-  Human, animal, and insect exposure
-  No data



**Mauritania**

**Regions with acute human RVF cases 1999-2021**



- 1999 - 2010
- 2011 - 2021
- Both Periods





**South Africa**

**Kenya**


**Madagascar**













Study name	Period	Time Interval	Statistics for each study				p-Value
			Odds ratio	Lower limit	Upper limit		
Sanderson (2020)	IEP	1985-2019	1.864	1.073	3.236	0.027	
Marrama (2005)	IEP	1999	1.130	0.717	1.778	0.599	
Swai (2009)	IEP	2004	3.675	0.445	30.373	0.227	
Porrut (2010)	IEP	2005-2008	1.768	1.260	2.481	0.001	
LaBeaud (2008)	IEP	2006	2.428	1.130	5.219	0.023	
Muiruri (2015)	IEP	2006	2.643	1.252	5.578	0.011	
Anyangu (2010)	Outbreak	2006-2007	1.424	1.036	1.958	0.030	
Aradib (2013)	Outbreak	2007	1.378	0.724	2.623	0.329	
Hassanian (2010)	Outbreak	2007	2.760	1.177	6.470	0.020	
Ochieng (2015)	Postepidemic	2007	1.283	0.751	2.192	0.362	
Al-Azraqi (2012)	IEP	2007-2008	0.949	0.647	1.390	0.787	
Heinrich (2012)	IEP	2007-2008	1.000	0.608	1.645	1.000	
LaBeaud (2011)	IEP	2009	2.324	1.173	4.603	0.016	
Byomi (2015)	IEP	2009-2010	1.379	0.717	2.650	0.335	
Grossi-Soyster (2017)	IEP	2009-2011	0.808	0.436	1.499	0.499	
Tigoi (2015)	IEP	2009-2012	0.720	0.417	1.242	0.238	
Andayi (2014)	IEP	2010-2011	1.170	0.483	2.833	0.727	
Cook (2017)	IEP	2010-2012	0.452	0.147	1.384	0.164	
Nakoune (2016)	IEP	2010-2012	1.866	0.704	4.945	0.210	
LaBeaud (2015)	IEP	2011	1.463	1.048	2.043	0.026	
Lernout (2013)	IEP	2011	1.453	0.822	2.566	0.198	
Gray (2015)	IEP	2012	0.985	0.531	1.828	0.962	
Sumnaye (2015)	IEP	2012	1.260	0.767	2.071	0.361	
Gudo (2016)	Outbreak	2013	1.531	0.605	3.875	0.369	
Bett (2019)	IEP	2013-2014	1.520	1.008	2.291	0.046	
Ahmed (2018)	IEP	2014	1.432	0.719	2.851	0.307	
Tigoi (2020)	IEP	2014-2015	1.670	1.168	2.387	0.005	
Nyakarahuka (2018)	Outbreak	2016	2.705	1.511	4.843	0.001	
<b>Pooled OR (random effects)</b>			<b>1.410</b>	<b>1.240</b>	<b>1.604</b>	<b>0.000</b>	




<u>Study name</u>	<u>Period</u>	<u>Time Interval</u>	<u>Statistics for each study</u>			
			<b>Odds ratio</b>	<b>Lower limit</b>	<b>Upper limit</b>	<b>p-Value</b>
Marrama (2005)	IEP	1999	0.649	0.336	1.256	0.199
Swai (2009)	IEP	2004	3.032	0.160	57.520	0.460
LaBeaud (2008)	IEP	2006	8.335	1.959	35.460	0.004
Muiruri (2015)	IEP	2006	3.596	0.824	15.701	0.089
Anyangu (2010)	Outbreak	2006-2007	2.060	1.408	3.014	0.000
Al-Azraqi (2012)	IEP	2008	1.961	1.073	3.582	0.028
Gray (2015)	IEP	2010-2012	0.810	0.428	1.535	0.519
Sumaye (2015)	IEP	2012	1.081	0.649	1.800	0.764
Bett (2019)	IEP	2013-2014	1.908	1.044	3.488	0.036
Tigoi (2020)	IEP	2014-2015	1.380	1.009	1.888	0.044
Nyakarahuka (2018)	IEP	2016	1.194	0.684	2.084	0.533
<b>Pooled OR (random effects)</b>			<b>1.457</b>	<b>1.092</b>	<b>1.944</b>	<b>0.010</b>



**Less likely      More likely**

<u>Study name</u>	<u>Period</u>	<u>Time Interval</u>	<u>Statistics for each study</u>			
			<b>Odds ratio</b>	<b>Lower limit</b>	<b>Upper limit</b>	<b>p-Value</b>
LaBeaud (2008)	IEP	2006	2.780	1.029	7.512	0.044
Muiruri (2015)	IEP	2006	5.320	2.491	11.361	0.000
Anyangu (2010)	Outbreak	2006-2007	3.830	1.619	9.062	0.002
Al-Azraqi (2012)	IEP	2008	11.583	6.950	19.306	0.000
Archer (2011)	Outbreak	2008	0.715	0.114	4.477	0.720
LaBeaud (2011)	IEP	2009	3.490	1.522	8.002	0.003
LaBeaud (2015)	IEP	2011	5.310	3.389	8.319	0.000
Lernout (2013)	IEP	2011	11.120	1.101	112.357	0.041
Memish (2015)	IEP	2012	3.200	1.168	8.764	0.024
Sumaye (2015)	IEP	2012	2.020	1.151	3.547	0.014
Msimang (2019)	IEP	2015-2016	1.724	0.965	3.079	0.066
<b>Pooled OR (random effects)</b>			<b>3.646</b>	<b>2.321</b>	<b>5.728</b>	<b>0.000</b>



**Less likely      More likely**